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Fliposomes with a pH-sensitive conformational switch for anticancer
drug delivery against triple negative breast cancer

Abstract

by Yifan Lu
University of the Pacific
2019

Cancer is the second leading cause of death in the US and worldwide, accounting for
16% of deaths worldwide in 2015. Of more than 100 types of cancers affecting humans, breast
cancer is the most common cancer among women and is the second leading cause of death in
women. Triple negative breast cancer (TNBC) is a subtype of breast carcinomas defined by the
lack of the expression of estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor (HER2 /neu). The prognosis and survival of TNBC patients
remains the poor due to the lack of effective targeted therapy.
Nanotechnology-based drug delivery systems, such as liposomes, are widely investigated
to enhance anticancer efficacy by concentrating the drug molecules in the tissues of interest and
by altering the pharmacokinetic profile. Taking advantage of the pH gradient in the tumor
microenvironment, pH-triggered release is a promising strategy to enhance the anticancer
efficacy of drug delivery systems against TNBC. Previously, a strategy in our lab has been
developed to render saturated and pegylated liposomes pH-sensitive: protonation-induced
conformational switch of lipid tails, using trans-2-aminocyclohexanol lipids (TACH, flipids) as a
molecular trigger. Based on previous work in our lab, pH-sensitive liposomes (fliposomes)
composed of C-16 flipids with amine group of morpholine (MOR) and azetidine (AZE)
demonstrated optimized triggered release in response to the tumor’s low pH microenvironment.
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In this study, different preparation methods were developed and optimized to produce
viable fliposomes with high doxorubicin (DOX) encapsulation efficiency. In vitro release assays
were established and validated to accurately reflect pH-triggered release of fliposomes. The
physicochemical properties of DOX-loaded fliposomes were characterized and their pHdependent release were investigated. Factors influencing the desirable attributes of liposomes,
such as size, pH-sensitivity, stability and drug-loading capacity were explored. Based on these
characterizations, central composite design (CCD) was utilized to optimize the formulation of
fliposome with two critical factors, flipids and cholesterol.
Cell viability assays on traditional monolayer and innovative three-dimensional
multicellular spheroids (3D MCS) of TNBC cell lines were conducted to evaluate the anticancer
efficacy of the resultant fliposomes in vitro. The constructed 3D MCS carried heterogeneously
distributed live and apoptotic cells, as well as acidity inside the 3D MCS based on confocal
microscopic imaging studies. The distribution and penetration of DOX-loaded fliposomes into
3D MCS was imaged by confocal microscopy in comparison to DOX-loaded non pH-sensitive
liposomes and free DOX. As a result, fliposome manifested superior anticancer activity against
TNBC 3D MCS by efficient penetration into 3D MCS, followed by tuning up the release rate of
the anticancer agent DOX.
A TNBC orthotopic xenograft model was established by transplanting TNBC into the
murine mammalian fat pad, which maintains the organ-specific tumor microenvironment of the
original organ. A pilot pharmacokinetic study was conducted in order to correlate the pH
response and stability properties with the in vivo stability of the optimized AZE-C16 fliposome.
The antitumor efficacy was comparable between free DOX and DOX-loaded stealth liposome
with tumor volumes of ~ 80-90% of the control treatment 32 days post first dose. In contrast, the
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DOX-loaded fliposome, especially MOR-C16 fliposome, exhibited a significantly higher
antitumor efficacy and delayed progression compared to free DOX and stealth liposome
treatments.
Taken together, DOX-loaded fliposomes were successfully prepared and optimized for in
vivo application. They were able to achieve superior activity against TNBC in vitro and in vivo,
facilitated by enhanced release of the anticancer drug DOX after penetration inside TNBC tumor.
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Chapter 1: Introduction

1.1 Statement of the Problem
1.1.1 Triple negative breast cancer (TNBC). Cancer is a large group of related
diseases that involves rapid and abnormal proliferation of cells with the potential to spread and
invade surrounding tissues [1]. Cancer is the second leading cause of death in the US and
worldwide, accounting for 16% of deaths worldwide in 2015 [2]. About 1.7 million new cases
of cancer and about 609,640 deaths have been estimated in the US for the year 2018 [1]. Of
more than 100 types of cancers affecting humans, breast cancer is the most common cancer
among women and is the second leading cause of death in women, exceeded only by lung cancer
[3]. Clinically, breast cancers can be divided into various subtypes by stage, pathology, grade or
the expression level of specific receptors [4, 5]. Triple negative breast cancer (TNBC), a subtype
accounting for approximately 15% to 20% of all breast carcinomas, is defined by the lack of
expression of the estrogen receptor (ER), the progesterone receptor (PR) and the human
epidermal growth factor receptor (HER2 /neu) [4, 6, 7]. It was reported that TNBC is much
more common in younger women and in women of African ancestry in addition to exhibiting
more BRCA1 mutations [8]. Although the population of TNBC is not the largest among various
subtypes of breast cancer, the prognosis for TNBC remains the poorest because it is more
aggressive and not responsive to targeted therapies that are effective to other subtypes of breast
cancer. Among breast cancer patients, those with TNBC have the poorest prognosis and the
shortest life span [7].
1.1.2 Treatment choices and chemotherapy. Patients with TNBC cannot benefit from
hormone therapy because the cancer is ER/PR-negative; they cannot benefit from Herceptinbased therapy because the cancer cells are HER2-negative. Therefore, surgery, radiation therapy
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and chemotherapy, individually or in combination, are the only available options for the TNBC
patients.
Surgery and radiotherapy are available options to patients with other subtypes of breast
cancer. Basically, there are 2 types of breast cancer surgery: lumpectomy and mastectomy, of
which the aim is to remove the entire tumor from the breast. Radiotherapy is typically conducted
in the TNBC patient following the surgery, more often in women having lumpectomy (breast
conserving surgery). It was reported that TNBC patients with the BRCA1 gene mutation are
potentially highly radiosensitive and benefit more from the radiotherapy [9].
Chemotherapy, individually or in combination with surgery or radiotherapy is
predominantly given to the patients with both early stage and advanced TNBC although there are
no standard guidelines for TNBC chemotherapeutic treatment [5, 10]. Generally, there are
different categories of chemotherapies based on the mechanism, including microtubule
stabilizers, DNA replication inhibitor, cell proliferation inhibitor and targeted therapies [10, 11].
Microtubule stabilizers are a group of microtubule-targeting agents that bind to
microtubules and increase the quantity of cellular microtubules by breaking the dynamics of
tubulin polymer during the mitotic stage of the cell cycle [12, 13]. Taxanes, including paclitaxel
and docetaxel, exhibit more potency against TNBCs than receptor-positive breast cancers. It was
reported that TNBC patients who received the treatment of fluororacil, epirubicin, and
cyclophosphamide (FEC) followed by weekly paclitaxel for 8 week benefit more than the patient
receiving FEC only [14].
Platinum compounds play a major role in treating TNBC. Carboplatin and cisplatin form
crosslinks within and between double-stranded DNA, which inhibits DNA replication. Hence,
platinums can overcome the DNA repair cascade caused by the BRCA mutation, making them

26
the primary option for the TNBC patient with BRCA mutation [15]. Although Zhang et al.
reported the cisplatin-based treatment have the best efficacy against TNBC, the platinums are
still recommended to be used with other chemotherapeutic drug to achieve better efficacy [16].
Anthracyclines, such as doxorubicin and epirubicin, are some of the most common and
most active drugs for the breast cancer treatment. It was found that the pathologic complete
response (pCR), disease-free survival (DFS) and overall survival (OS) are improved with the use
of neoadjuvant chemotherapy, in which anthracycline-based regimen is frequently utilized.
Carey et al. reported that doxorubicin and cyclophosphamide treatment showed better clinical
sefficacy on TNBC patients than non-TNBC patients [17]. In addition, DNA damage caused by
anthracycline can also bypass the effect of BRCA mutation [18]. 57.1% vs 29% pCR rates were
found between BRCA1 mutated and wild type TNBC patients after being treated with
anthracycline and taxane regimens, respectively [19].
In addition, targeted chemotherapy, which aims at particular growth factor or receptor is
also widely used in the treatment of TNBC. Examples of targeted therapy include PARP
inhibitors, angiogenesis inhibitors, EGFR inhibitors, TK inhibitors and mTOR inhibitors [10].
Immunotherapy, such as checkpoint inhibitors, has also emerged to improve the outcome of
advanced-stage TNBC in combination with chemotherapy [20].
1.1.3 Doxorubicin: Pros and cons. Doxorubicin (DOX or DXR) (Figure 1.1), which
was first extracted from the actinobacteria Streptomyces peucetius var. caesius, is one of the
most commonly used anthracyclines [21]. DOX belongs to the antibiotic category of cytotoxic
anticancer drugs [22]. DOX is indicated in the treatment of various cancers including breast
cancer, ovarian cancer, lung cancer, neuroblastoma, gastric cancer, Hodgkin lymphoma and
acute lymphocytic leukemia[23-25]. It is administrated by an intravenous injection through
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catheter to prevent extravasation and is often used in a combination with other chemotherapy
drugs [17, 19, 26].
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Figure 1.1. Chemical Structure of Doxorubicin

The cytotoxicity of DOX is cell cycle-nonspecific but peaks in the S phase. Several
mechanisms have been proposed to explain the anticancer activity of DOX, of which two major
ones are widely accepted (Figure 1.2). One is inhibition of macromolecular biosynthesis by
intercalation into DNA and another is cell membrane damage through the generation of free
radicals and reactive oxygen species (ROS) [27-29]. The intercalation of DOX into DNA causes
inhibition of the function of the topoisomerase II (TOP II) complex, an enzyme responsible for
relaxing supercoils in DNA during transcription [27, 30, 31]. Regarding free radical generation,
DOX is reduced by the ubiquitous oxidoreductases to form unstable DOX-semiquinone radicals,
which carry out one-electron reduction of molecular oxygen to generate reactive oxygen species
(ROS) that lead to lipid peroxidation and membrane damage, DNA damage and oxidative stress,
eventually triggering apoptotic pathways of cell death [29, 32].
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Figure 1.2. Mechanism of action of doxorubicin (candidate genes involved in the action of
doxorubicin in a stylized cancer cell) [33].

After the approval of DOX in 1974, it took 20 years to see the approval of paclitaxel for
metastatic breast cancer [34]. The ability to arrest the cell cycle at all stages and the broadspectrum antineoplastic activity makes DOX most widely used in cancer therapy. However, the
clinical use of DOX is still restricted by several side effects (Table 1.1), especially dosedependent cardiotoxicity [35, 36]. The development of liposomal DOX was based on the
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rationale, that the DOX encapsulated inside liposome cannot extravasate in areas with tight
capillary junctions such as heart muscle but can escape where the vasculature is not tighty
jointed such as in solid tumors [37]. Hence, the first nanotechnology-based drug Doxil® carries
less cardiotoxicity than the free DOX, and was approved in 1995 [38].

Table 1.1. Adverse effects associated with doxorubicin [37]
Category
Adverse events
Hematologic
Bone marrow depression especially of
neutrophils and platelets
Dermatologic
Photosensitivity, itching, rash
Gastrointestinal
Nausea, vomiting, oral ulceration, lopecia,
diarrhea
Cardiovascular
Acute cardiotoxicity
Tachycardia, hypotension and various
Electrocardiography (ECG) changes due to
arrhythmia
Chronic
Cardiomyopathy leading to congestive
cardiotoxicity
cardiac failure
Renal
Glomerular atrophy and increase
glomerular permeability

Another practical reason leading us to select DOX as a cargo drug is its unique spectral
property. DOX is a fluorescent molecule which is typically excited at 485 nm and emits high
quantum yield fluorescence between 560 - 590 nm. Such a long wavelength allows us to
conduct visualized experiments to investigate the DOX’s distribution in vitro.
1.1.4 Barriers in drug delivery to TNBC. TNBC is considered as a malignant solid
tumor, which is an abnormal growth of cells that forms a mass in a solid tissue. The
physiological characteristics of a solid tumor (Figure 1.3) are distinct from normal tissue,
including neovasculature, interstitial pressure, and multiple gradients of nutrients, oxygen and
therapeutic agents. Newly formed blood vessels are structurally and functionally abnormal [39].
The distribution of blood vessels in a solid tumor is also heterogeneous, ranging from well
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perfused periphery to avascular necrotic core, which increases the difficulty to sufficiently
deliver anticancer agents into all the cancer cells. In addition, the high interstitial pressure in
tumors compared to normal tissues leads to a net outward flow from the core of the tumor. It
was reported that the elevated interstitial fluid pressure of a solid tumor may aggravate the
gradients of angiogenic factor that are released into the surrounding tissues [40]. Furthermore,
the abnormal lymphatic function, the elevated interstitial hydraulic conductivity as well as the
collapse of tumor lymphatic drainage are the main causes of the interstitial fluid pressure inside
the solid tumor [40].
To exert its activity, an anticancer drug has to avoid quick clearance and distribute
sufficiently to the blood vessels of a tumor, then permeate through the tumor blood vessels
efficiently, then translocate through the interstitial matrix to penetrate deep into the tumor [41].
The extravasation and the penetration are largely affected by the physiochemical properties of
the compound, such as size, charge, and solubility in water and lipids. The penetration and
transport through the tumor interstitium are mainly controlled by diffusion, which is governed by
concentration gradient. However, ionization of the drug molecule in the tumor
microenvironment will increase its interaction with the extracellular matrix and thus hamper
diffusion. One example would be doxorubicin, a weak base, getting protonated and then stuck in
the acidic organelles and interstitium. The transport of larger molecules is mainly governed by
convection, which depends on the hydraulic conductivity and pressure difference. Specifically,
extravasation of macromolecules will be drastically decreased by the high interstitial fluid
pressure of the solid tumor. Furthermore, the well interconnected structure of extracellular
matrix, such as collagen, will decrease the penetration of high-molecular-weight drugs [42]. All

31
those characters in solid tumor are all present in TNBC and create a dreadful barrier to the
delivery of anticancer drugs against TNBC.

Figure 1.3. Physiological Characteristics of Tumor Tissue and Vasculatures [43]

1.2 Strategies for Effective Delivery of Doxorubicin to Solid Tumors
1.2.1 Targeted delivery. An ideal drug delivery system has to overcome the above
mentioned barriers in order to improve therapeutic efficacy and to minimize adverse effects of
the cargo drug. Targeted drug delivery provides one of the solutions by modifying the
pharmacokinetics profile, especially the distribution of anticancer agents. Generally, there are
two broad classes of drug targeting, namely passive targeting and active targeting [44, 45].
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1.2.1.1 Passive targeting. Passive targeting, also called physical targeting, achieves the
desired accumulation of therapeutic agent at the target site by catering the physicochemical
properties of the drug delivery system to the distinctive characteristics of the pathologic
tissue/organ. The enhanced permeation and retention (EPR) effect, one of mechanisms of
passive targeting (Figure 1.4), was proposed in 1986 as an innovative strategy to deliver
macromolecular drugs to tumors [46]. The enhanced permeation of nanocarriers or
macromolecules at the tumor site is caused by tumor vascular leakage while the enhanced
retention occurs due to the impaired lymphatic drainage within neoplastic tissues [47]. The cutoff size of the permeabilized vasculature varies, but 200 nm in diameter or below is generally
accepted for the solid tumor vasculature [48]. Nevertheless, an extended period of circulation in
the blood is required for this type of drug delivery system to achieve sufficient accumulation in
the tumor. Besides keeping the molecular weight above 40 kDa to circumvent renal filtration,
the common way to keep the nano-drug delivery system in the blood stream is to disguise them
by grafting their surface with polyethylene glycol (PEG). This hydrophilic polymer minimizes
the adsorption of serum proteins to prevent opsonization and thus hinder their recognition and
clearance by the reticuloendothelial system (RES) [49]. Generally, the higher average molecular
weight of PEG leads to longer systemic circulation time, except that liver clearance is found to
be enhanced when the average molecular weight of PEG goes over above 50 kDa [50]. In
addition, prolonged circulation makes it possible to maintain therapeutic concentrations of drug
or drug delivery system in the blood for a relatively long time even after a single dose.
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Figure 1.4. Diagrammatic representation of EPR effect [51].

It must be noted that there are several challenges in passive targeting for anticancer drug
delivery. First, the EPR effect varies by the different structures of various tumors. For instance,
hepatic and renal carcinoma show relatively strong EPR effect due to the high vascular density,
while pancreatic and prostate cancers show less EPR effect [46]. In addition, the heterogeneity
within one solid tumor also creates an imbalance of the EPR effect. It is reported that the central
necrotic area of metastatic cancers doesn’t exhibit the EPR effect due to the lack of vasculature
[52, 53]. This phenomenon makes penetration the limiting step to achieve the desired
therapeutic efficacy. Furthermore, tumor growth rate and tumor size in animal models are not
comparable to that in humans, leading to differences of EPR effect between tumor and tumor
xenografts [54]. Rodent tumor models always have tumors at least 5 mm in diameter during the
late stage and a larger tumor is more likely to have hypovascular areas in the necrotic core.
Moreover, the resistance of the capillary wall to the move of macromolecules or drug delivery
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system getting into tumor interstitial space, which is significantly greater than subsequent
resistance, is a noticeable factor that affects the outcome of the EPR effect [55].
1.2.1.2 Active targeting. In general, active targeting involves coupling specific targeting
ligands to the surface of the drug carrier so that it can selectively bind to target receptors
expressed on the surface of particular cell, tissue or an organ [56, 57]. The strong interaction
between the ligand and receptor is so selective that the unwanted non-specific binding in
peripheral tissues and toxicity will be reduced. Because some receptors manifest higher
expression in the tumor cells or tumor vasculature cells than normal cells, a solid tumor is highly
likely to get benefits of active targeting therapy. It is also reported that the activation of
receptor-mediated endocytosis by such specific binding can suppress multidrug resistance
because it circumvents drug efflux by P-glycoprotein [58]. Tremendous effects were put into
developing novel targeted delivery systems for diagnostic and therapeutic applications in various
diseases. The active targeting ligands that are exploited in those systems include antibodies,
antibody fragments, aptamers, peptides, proteins and some small molecules which are known as
receptor ligands [59]. Currently, antibody-drug conjugates (ADCs), which currently represent
the leading class of biopharmaceutical drugs, is an eminent example of the active targeting
strategy. All the four approved ADC products are utilized to treat various types of cancer, which
suggests the great clinical response to this strategy of treating cancer. Unfortunately, TNBC is
so far known to have no potential target receptor to take advantage of active targeting.
1.2.2 Liposomes. As one of the nanocarriers, liposomes are nano-sized vesicles
composed of amphiphilic molecules such as phospholipids, which form a closed bilayer structure
that encloses a central aqueous compartment [60-62] (Figure 1.5). Liposomes have a spherical
shape with the size ranging from 20 nm to a few microns in diameter. Typically, the hydrophilic
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drug molecules can be encapsulated in the aqueous core while lipophilic drugs can be
incorporated in the lipid bilayer (Figure 1.6), which enables liposomes to deliver a variety of
cargo molecules including small molecules, proteins, nucleotides and even plasmids [61].
Liposomes can be categorized into the following types based on the numbers of concentric lipid
bilayers and the size: multilamellar vesicle (MLV), small unilamellar vesicle (SUV) and large
unilamellar vesicle (LUV) [63].
From the perspective of biomedical application, liposomes consist of biocompatible
material which won’t cause severe allergic or toxic reactions and will eventually be broken down
through biological pathways [64]. Liposomes can protect the entrapped cargo molecules,
especially proteins and nucleotides from the inactivating effect of the physiological media [44].
It was also reported that liposomes can fuse with the cell surface to deliver agents into cell [65].
From the perspective of clinical application, liposomes are capable of altering the biodistribution and the rate of clearance of the contents entrapped, which results in the drastic
change of the pharmacokinetic parameters [64]. The physicochemical properties of the
liposome, such as size, surface charge and steric stabilization are the main factors affecting the
pharmacokinetic profile. Besides these features, the surface of the liposomes can be grafted with
various molecules to enhance their stability in blood circulation and/or to increase their specific
targeting to certain cells/tissues. The first liposomal pharmaceutical product Doxil® (Janssen
Products, LP, Horsham, PA) was approved by the FDA to treat Kaposi’s sarcoma and breast cancer

in 1995 and 2003, respectively [38, 66]. There are currently more than ten marketed liposomal
products and hundreds of new products are in various stages of clinical trials.
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Figure 1.5. The self-assembly of individual amphiphilic lipids (a) to bilayer (b) and then to
closed liposomes (c). A single bilayer is typically ~5 nm thick and consists of neatly arranged
individual lipid molecules with their hydrophilic heads facing the internal and external aqueous
media and their hydrophobic tails packed inside the bilayer (d) [67].

Figure 1.6. Drug loading in liposome: soluble hydrophilic drugs are entrapped into the aqueous
interior of the liposome ( ), while poorly soluble hydrophobic drugs are localized in the
liposomal membrane ( )
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1.2.2.1 Conventional liposomes. Conventional liposomes, sometimes termed classical
liposomes or 1st generation liposomes, are made up of neutral and/or negatively charged
phospholipids and cholesterol. Some of these formulations are on the market already, such as
Ambisome® (Gilead Sciences, Foster City, CA), Daunoxome® (Gilead Sciences) and Myocet®
(Elan Pharmaceuticals Inc., Princeton, NJ). It was observed that conventional liposomes are
rapidly captured by cells of the RES and eliminated from blood circulation, leading to their
relative short half-life [68]. This in vivo attribute of conventional liposomes was exploited to
develop antiparasitic and antimicrobial drugs in order to treat infections because both the
liposomes and the pathogen cells accumulate to the RES [69, 70]. It was also reported that
increasing size of conventional liposomes would enhance uptake in the RES, primarily in the
liver, leading to more rapid hepatic clearance [71]. Furthermore, it was found that drug leakage
from conventional liposomes is associated with their interaction with high and low density
lipoproteins in the plasma, especially when the conventional liposome does not carry cholesterol
in the lipid membrane [72, 73]. As mentioned above, the application of conventional liposome is
limited when the target site is beyond RES.
1.2.2.2 Stealth liposomes. The incorporation of saturated phospholipids with high
transition temperature (Tm) and cholesterol into the bilayer structure still cannot fully overcome
the in vivo stability issue caused by opsonization. In order to target tissues other than the RES
system, liposomes need to minimize interaction with the RES so as to prolong their half life in
blood circulation. Several strategies in this regard have been developed. The surface of the
liposome can be grafted with monosialoganglioside [74] to generate new “stealth liposomes”
with a more hydrophilic surface [75] that decrease the liposomes’s interaction with RES. The
most popular and successful method to generate “stealth liposomes” is to coat the liposome
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surface with hydrophilic polymers, such as poly (ethylene glycol) (PEG). The basic mechanism
is that the hydrophilic polymer molecules with a flexible chain occupy the space adjacent to the
surface of liposome and thus form a steric protective layer to hinder the binding of other
macromolecules such as opsonin, thereby slowing down the liposomes’ recognition by the RES
and subsequent clearance [62, 64, 72]. Moreover, it was reported that the PEG chains on the
liposome surface provide strong repulsion between membranes to prevent liposome aggregation,
thus improving the stability of formulations [76]. In this way, the EPR effect can be enhanced
due to the sufficient time available for the stealth liposomes to accumulate in the solid tumor,
which results in improvements in the therapeutic outcomes compared to conventional liposome.
As an example, Doxil® as a representative of stealth liposome was approved to treat AIDSrelated Kaposi's sarcoma.
1.2.2.3 Stimuli-responsive liposomes. It must be kept in mind that only the drug
molecules that are released from liposomes can exert their biological function. Thus, the
therapeutic efficacy of liposome formulations can improve only when the rate of drug release
from liposomes is elevated at the target tumor [77, 78]. The stability of PEGylated liposomes
may not always favor more biological effect, especially if it does not increase the distribution of
the cargo drug molecules inside the target cells. An ideal liposomal drug delivery system should
remain stable during blood circulation until it is delivered to the disease site, and then elevate the
release of its cargo drug molecules in response to a specific stimulus at the target site. The
stimulus can be internal or external. The former is endogenous stimuli presented in various
physiological environments, such as low endosomal pH [79], raised temperature at inflammatory
tissue [80] and specific enzymes in a particular microenvironment [81]. The latter is the stimuli
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from external sources, which include ultrasounds [82], light [83], magnetic field [84] and electric
field [85]. Typically, the application of external stimuli requires particular facilities.
If a stimuli-responsive lipid component is incorporated into the stealth liposome, the
liposome can then be developed into a “smart” delivery system to achieve controlled release as a
“magic bullet”.
1.2.3 pH-sensitive lipids and fliposomes. Among the above mentioned stimuli, pH
gradients have been widely investigated because they are present at various organs, tissues and
cell levels within body (Figure 1.7) [86]. It is widely recognized that the acidic extracellular
microenvironment is the most prevalent attribute among various types of tumors except for blood
carcinomas. Generally speaking cancer cells have an intracellular pH (pHi ) of 7.4 and a lower
extracellular pH (pHe) of ~6.7 while the reverse pattern is observed in normal cells (pHi= ~7.2
and pHe= ~7.4) [87]. As the solid tumor grows, cancer cells become farther from the basement
membrane and vasculature, leading to the low oxygen supply. The high consumption of energy
required for cancer cell survival is compensated by the upregulation of glycolysis [88-90].
Simultaneously, HIF-1α expression is activated and promotes the activation of multiple genes
including those encoding pH regulators, leading to the overexpression of Na+ -H+ exchanger
NHE1 of the SLC9A family and the monocarboxylate - H+ efflux cotransporters MCT1 and
MCT4 of the SLC16A family [87, 88] (Figure 1.8). All these pathways, together with the
absence of lymphatic drainage contribute to the acidification of the tumor microenvironment. It
was reported that decreased pHe is associated with a tumor’s escape from immune detection and
eventually cancer progression and metastasis [90, 91]. Furthermore, at subcellular level the pH
in endosomes and lysosomes can reach as low as 4.5-5.5 [92].
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Figure 1.7. Examples of different physiological pHs available for pH-sensitive drug delivery
targeting. a) Targeting at the organ level: the GI tract is characterized by a pH gradient. b)
Targeting at the tissue level: solid tumors exhibit an acidic extracellular microenvironment. c)
Targeting at the cellular level: endo-lysosomes are more acidic compared to the cytoplasm
(shown in red) [86].

Figure 1.8. Mechanisms of pH decrease in the tumor microenvironment [88]

As mentioned above, pH gradient could be an excellent trigger to elevate the release of
therapeutic agent from stimuli-response liposomes. Most of the reported work on pH-sensitive
liposomes takes advantage of the dramatically more acidic environment of endosomes/lysosomes
[93, 94]. While the pH in the tumor interstitium is slightly lower than the one in blood, it is
rarely below 6.5, which makes it difficult for the pH-sensitive liposomes to release more drugs
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[95]. Many approaches have been tried to render stealth liposomes pH-sensitive, including
incorporation of pH-sensitive fusogenic peptides [96, 97], coating the liposomes with polyanions
[98, 99] and incorporation of the phase transition lipid PE [100].
Various pH-sensitive lipids were designed and synthesized previously in our lab [101,
102]. A conformationally controlled molecular switch has been designed to destabilize the
liposome membrane in response to a pH drop and was reported by our group and collaborators
[103][104]. The mechanism of the membrane destabilization is that an intramolecular hydrogen
bond between the protonated amine group and its neighboring hydroxyl group induces a
conformational change of the cyclohexane ring in the lipid, leading to the axial positional
transformation of the lipid tails [105] (Figure 1.9). In stealth liposome comprising such pHsensitive lipids, the conformational switch can destabilize the lipid bilayer, thus increasing the
rate of content release (Figure 1.10). Lipids with this kind of conformational switch are named
“flipids” and the liposomes containing flipids are called “fliposomes” [106-108]. In order to
fulfill the prerequisite of stability, flipids with saturated hydrocarbon chains at the length of 16
carbons were selected to develop fliposomes for the treatment of TNBC. With preliminary data,
flipids with amine group of morpholine (estimated pKa in methanol = 4.9) and azetidine
(estimated pKa in methanol = 6.8) (Figure 1.11) fit into the narrow range of pH gradient in tumor
microenvironment for the TNBC treatment [104].
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Figure 1.10. Perturbation of lipid bilayer and drug release induced by pH-Triggered
conformational switch
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Figure 1.11. Chemical structure and Estmated pKa in methanol of MOR-C16 and AZE-C16
[104]

1.3 Hypothesis and Specific Aims
Based on the foregoing review of the literature, we hypothesize that pH-triggered release
from liposomes can improve physical targeting, consequently the efficacy of doxorubicin against
triple negative breast cancer. Accordingly, select fliposomes loaded with doxorubicin were
prepared by different methods and characterized in vitro to investigate the triggered release in
response to the acidic pH that mimics the acidic tumor microenvironment. The optimization of
select fliposome was conducted to further fulfill the prerequisite for in vivo application.
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Afterwards, the anticancer efficacy of the resultant fliposomes was evaluated in both 2D
monolayer TNBC cells and in 3D MCS of TNC cells in vitro. Finally, the anticancer activity of
select flipsomes were also evaluated in an orthotopic xenograft model of TNBC. The
comparison of anticancer efficacy in vitro and in vivo between fliposome and corresponding non
pH-sensitive liposomes was conducted to evaluate the improvement due to pH-triggered release.
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Chapter 2: Preparation and Characterization of pH-sensitive Fliposome

2.1 Introduction: Strategies to Prepare pH-sensitive Liposomes
It is widely known that liposomes are mainly composited with natural and/or synthetic
lipids, which are classified as amphiphilic molecules. Once those molecules are exposed to
aqueous solution, they tend to form aggregated complexes so as to minimize entropically
unfavorable interactions between their hydrophobic moieties and the surrounding water
molecules. Numerous techniques and methods have been developed to prepare liposome
formulations since their discovery by Bangham et al in 1965 [109]. The formation of liposomes
requires a sufficient amount of energy to form a thermodynamic system, therefore dispersion is
the key step with various techniques. Accordingly, liposomal preparation falls into two
categories: mechanical dispersion methods and solvent dispersion methods [110-113].
The mechanical dispersion methods include the following types: thin-film lipid
hydration, sonication, freeze-thawing, and membrane extrusion. These methods could be
performed individually or in combination depending on the nature of the formulation
components. Thin-film hydration was originally invented by Bangham [109], in which the
mixture of lipids was first dispersed in an organic solvent. Then the solvent was removed under
vacuum to obtain a thin layer of lipid film deposited at the bottom of flask. Hydration buffer was
added under agitation at a temperature above the lipid transition temperature (Tm) [109]. By this
method, multilamellar liposomes (MLVs) with size ranging from 0.5 µm to 5 µm could be
obtained. Typically, further size reduction was required to attain smaller and uniformly sized
formulations. Sonication is one of the methods to reduce the size. A bath or probe tip sonicator
is required for producing small unilamellar vesicles (SUV). However, sonication can degrade
the lipids and the encapsulated compounds, in addition to the drawback of decreasing the
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liposomes’ internal volume [110]. The process of quick freezing and slow thawing forms
unilamellar vesicles by reorganizing the structure of SUV[114, 115]. Extrusion through
polycarbonate filters with different pore size above Tm is another method widely implemented to
reduce the liposome size.
The commonly used solvent dispersion methods are solvent injection and reverse phase
evaporation [113]. The solvent injection method involves dissolution of the desired lipids into
an organic solvent (ethanol or ether), then the injection of the organic solvent into aqueous media
to form the liposomes. The difference between the two organic solvent is the method to remove.
Ether is removed by evaporation at elevated temperature or under reduced pressure, while
ethanol is removed by dialysis or diafiltration because it is miscible with water. Both of the
injection methods have the disadvantage of heterogeneity of the resultant formulation. The
reverse phase evaporation method results in the fusion of micelles into liposomes during the
evaporation of the organic solvent. When the gel eventually collapses after evaporation, some of
the phospholipids form bilayer structures around the residual micelle to form liposomes. This
method has the advantage of high loading efficiency by creating a higher aqueous space-to-lipid
ratio, while carrying the disadvantage of possible degradation of the lipids and the loading
content by sonication during the micelles’ formation [112, 113]. Solvent dispersion could be
combined with appropriate mechanical dispersion to form smaller and more homogenous
liposomes.
In addition, new large-scale liposome preparation techniques, such as spray-drying,
freeze-drying and microfluidics, have emerged in response to the demand for industrial scale
production. Several modified ethanol injection methods have been applied to large scale
liposome manufacturing [116].
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In this study, a sequential combination of mechanical dispersion methods including lipid
film hydration, freeze-thawing, and finally membrane extrusion was well-established in our
group. Moreover, we have established the ethanol injection method because it is widely used in
industrial production. The procedure of the method includes ethanol injection followed by
diafiltration. In addition, sonication was also involved before drug loading in case that the size
of resultant after extrusion was not small enough. The aim of this chapter’s studies is to establish
robust preparation method of DOX-loaded fliposome.
2.2 Materials and Methods
2.2.1 Materials. The lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC), N-palmitoyl-sphingosine-1(succinyl[methoxy(polyethylene glycol)2000]) (PEG-ceramide (2000)), 1,2-dipalmitoyl-snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)) were
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Cholesterol, copper(II) Dgluconate, octaethylene glycol monododecyl ether (detergent OGME/C12E8), Dowex® 50WX4, 2-Amino-2-(hydroxymethyl)propane-1,3-diol (Tris) and triethanolamine (TEA) were
purchased from Sigma-Aldrich. Doxorubicin Hydrochloride was purchased from Biotang
(Waltham, MA, USA). Calcein, sucrose and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) were purchased from Fisher Scientific. All other organic solvent
and chemicals were purchased from Sigma Aldrich, Fisher Scientific or VWR.
2.2.2 Preparation of DOX-loaded liposomes.
2.2.2.1 Preparation of DOX-loaded liposomes by thin-film hydration coupled with
freeze-annealing-thawing. Generally, empty liposomes were prepared with thin-film hydration,
followed by extrusion based on prior reports [102, 108]. Chloroform and dichloromethane
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solutions of various lipids were mixed in a 25 mL round bottom pear-shaped flask. The traces of
organic solvent were removed by evaporation on a Buchi rotavapor and further drying in high
vacuum overnight at room temperature. The thin-film of lipids at the bottom of the flask was
hydrated with 30 mM HEPES buffer (pH 7.4) containing 300 mM MnSO4 or 375 mM TEA
buffer (pH 8.0) containing 100 mM Cu-Gluconate in a 60 °C water bath. The flask was filled
with argon followed by parafilm sealing. Intermittent agitation and vortexing were applied to
facilitate the hydration to obtain a liposome suspension of 20 mM total lipids. The liposome
suspension was followed by freeze-annealing-thawing procedure (sequentially immersion in
liquid nitrogen, ice-and-water mixture and 60 °C water bath until the temperature was
equilibrated respectively) for seven times. Then the liposome suspension was sequentially
extruded at least eleven times through 400 nm, 200 nm and 100 nm polycarbonate membranes
(Nucleopore Corp., Pleasanton, CA, USA) using a hand-held Mini-extruder (Avanti Polar Lipids
Inc., Alabaster, AL, USA) or three times using a high-pressure nitrogen Lipex® extruder
(TRANSFERRA Nanosciences Inc., Burnaby, B.C., Canada) at 60 °C.
In order to establish a transmembrane metal salt gradient, the extruded liposomes were
run through a Sephadex G-75 size exclusion column (SEC) (Sigma Aldrich, St. Louis, MO,USA)
which was pre-equilibrated with isotonic buffer containing 5 mM HEPES and 140 mM saline
(pH 7.4) or 10 mM Tris in 10% sucrose solution (pH 8.0). Doxorubicin was dissolved in the
same isotonic buffer at the concentration of 2 or 4 mg/mL. After passing through SEC, the
empty liposome suspension was promptly mixed with the previously described DOX solution in
1:1 volume/volume ratio and incubated at 60 °C for 40 minutes [117]. The cation-exchange
resin Dowex® 50WX-4 (Sigma Aldrich, St. Louis, MO, USA) was pretreated as previously
reported [118] and was mixed with liposome preparation at weight ratio of resin: DOX = 60 :1
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and gently shaken for 25 minutes at room temperature. During the incubation period, the
positively charged, free DOX binds to the Dowex resin, while the entrapped DOX remains
associated with the liposomes. The Dowex was removed from the DOX-loaded liposomes by
filtration of the mixture through 25 gauge syringe needle. The resultant liposome preparations
were stored at 4 °C in brown glass vials that were filled with argon until further studies.
2.2.2.2 Preparation of DOX-loaded liposome by ethanol injection. The desired lipids
were dissolved into absolute ethanol above the lipids transition temperature (60°C). The 30 mM
HEPES buffer (pH 7.4) containing 300 mM MnSO4 or 375 mM TEA buffer (pH 8.0) containing
100 mM Cu-Gluconate was equilibrated at 60°C in a hot water bath. Then the lipid ethanol
solution was injected into aqueous media. Liposomes formed spontaneously with mild shaking
and agitation. The solution was sequentially passed 3 times through polycarbonate membranes
of 400, 200, 100 nm pore size using a high pressure nitrogen Lipex® extruder (TRANSFERRA
Nanosciences Inc., Burnaby, B.C., Canada) at 60°C. The unloaded MnSO4/Cu-Gluconate were
removed by hollow-fiber diafiltration (MicroKros Spectrum Laboratories, Inc., Rancho
Dominguez, CA, USA) to establish the transmembrane metal salt gradient and to eliminate
ethanol from the formulation out of safety concern. The resultant liposomes were concentrated
by hollow-fiber diafiltration to a lipid concentration of 15~20 mM, then mixed with the
previously described DOX solution in 1:1 volume/volume ratio and incubated at 60 °C for 40
minutes. Purification was as described in 2.2.2.1.
2.2.3 Preparation of liposomes encapsulating calcein. Chloroform and
dichloromethane solutions of various lipids (Table 2.3) were mixed in a 25 mL round bottom
pear-shaped flask. The organic solvent was removed by evaporation on a Buchi rotavapor
followed by further drying in high vacuum overnight at room temperature. The thin-film of
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lipids at the bottom of the flask was hydrated with 100 mM Calcein (pH 7.4) in a 60 °C water
bath. The flask was filled with argon, capped and sealed with parafilm. Intermittent agitation
and vortex were applied to facilitate the hydration and obtain a liposome suspension of 20 mM
total lipids. The liposome suspension was freeze-annealing-thawing (sequentially immersion in
liquid nitrogen, ice-and-water mixture and 60 °C water bath until the temperature was
equilibrated respectively) for seven times. Then the liposome suspension was sequentially
extruded at least eleven times through 200 nm and 100 nm polycarbonate membranes
(Nucleopore Corp., Pleasanton, CA, USA) using a high pressure nitrogen Lipex® extruder
(TRANSFERRA Nanosciences Inc., Burnaby, B.C., Canada) at 60°C. The resultant liposome
suspension was passed through a Sephadex G-75 size exclusion column pre-equilibrated with
isotonic saline containing 5 mM HEPES at pH 7.4 to remove the unencapsulated calcein. The
liposome preparations were stored at 4°C in brown glass vials that were filled with argon.
2.2.4 Physicochemical characterizations of liposomes. The sizes and ζ-potential of the
liposome preparations were measured by photon correlation spectrometry and electrophoresis
mobility under applied voltage, respectively, using Zetasizer ZS 90 (Malvern Instruments Ltd.,
Malvern, UK).
2.2.5 Quantitation of DOX concentration and encapsulation efficiency of DOXloaded liposomes. An aliquot (10 µL) of DOX-loaded liposome was lyzed with 90 µL lysing
buffer (90% isopropanol containing 0.075 M HCl) [119]. The fluorescence of solution was
measured at 485 nm (excitation) and 590 nm (emission) on the Synergy HT microplate reader
(Biotek, Winooski, VT, USA). The concentration of DOX was quantified from a calibration
curve of DOX standard solutions (1, 2, 5, 10, 20, 50, 100 µg/ml) which were operated under the
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same lyzing procedure. The encapsulation efficiency (EE) of liposome preparation can be
calculated by the formula:

𝐸𝐸 =

𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛𝑠𝑖𝑑𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
× 100%
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑎𝑑𝑑𝑒𝑑 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔

2.3 Results and Discussion
2.3.1 Size, ζ-potential and polydispersity index (PDI) of liposome formulations.
After preparation by either thin-film hydration or ethanol injection, the liposomes of various
compositions presented similar average sizes, smaller than 200 nm after passing through 100 nm
polycarbonate membranes. The Polydispersity Index (PDI) of all preparations was lower than
0.3, which is the key indicator of homogeneity of colloids. No detectable ζ-potential for all
formulations suggested neutral charge of the whole system at pH 7.4, which would be expected
from the neutrally charged lipid components of the liposomes. The average size, PDI and
encapsulation efficiency of selected DOX-loaded liposomes are shown in Table 2.1.

Table 2.1. Size, PDI and EE of DOX-loaded liposomes by different preparation methods
Liposome

Molar Ratio Method

Size (nm) PDI.

EE (%)

MOR-C16/DPPC/PEG-DPPE

25/70/5

Thin-film

170.5

0.064

100

AZE-C16/DPPC/PEG-DPPE

25/70/5

Thin-film

119.8

0.165

86

MOR-C16/DSPC/Chol/PEGCeramide

30/40/25/5 Thin-film

189.1

0.188

88

MOR-C16/DSPC/Chol/PEGCeramide

30/40/25/5 EtOH Inj.

129.6

0.261

94

DPPC/Chol/PEG-Ceramide

50/45/5

Thin-film

110.2

0.097

65

DPPC/Chol/PEG-Ceramide

50/45/5

EtOH Inj.

124.9

0.220

56
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It is widely acknowledged that the size of drug delivery systems has prominent influence
on their pharmacokinetics profile and tissue distribution [120]. For tumor treatment,
nanocarriers with only size lower than 150 nm can get into the tumor interstitium by escaping
from the fenestrated capillaries of solid tumors [120-122]. However, 200 nm is the cut-off size
for the drug delivery system to take advantage of the EPR effect for tumor treatment [46, 123].
It is reported that nanocarriers with size ranging from 100 to 150 nm were not able to extravasate
into normal tissues in kidney, lung and heart [120, 122]. In this study, we have developed robust
preparation methods and procedures to strictly control the size of liposomes under 200 nm.
Therefore, all of these liposomes could serve as a viable nano-drug delivery system for
anticancer treatment.
2.3.2 Encapsulation efficiency (EE) of DOX-loaded liposomes. As shown in Table
2.1, the encapsulation efficiencies of DOX-loaded liposomes achieved 80% to 100% payload
with concentration ranging from 1 mg/ml to 2 mg/ml by the remote loading method except for
the conventional liposome with DPPC, Cholesterol and PEG-lipids.
To be sufficient for animal studies, 2 mg/ml or higher DOX concentration in the final
formulation was the goal for the all preparations. For the payload drug Doxorubicin, remote
loading, also known as active loading, was a well-established procedure to achieve high loading
efficiency and a high enough concentration. The transmembrane ion gradient was the driving
force to pump the payload drug molecules into the liposome aqueous core, while their
precipitation with either sulfate or metal ion enables high payload retention. Besides pH
gradient, ammonium sulfate gradient is the most commonly utilized method in the industry
manufacture. Metal salt, such as manganese sulfate or copper gluconate were reported to
achieve similar loading ability by forming metal-doxorubicin complex which is favored when the
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intraliposomal pH >6.5 [60, 124]. In this project we utilized either the manganese sulfate or the
copper gluconate gradient for the remote DOX loading since it circumvented the low pH of the
ammonium sulfate solution during the drug loading.
2.3.3 Comparison of different preparation procedure.
2.3.3.1 Mini-extruder versus nitrogen Lipex extruder. As shown in Table 2.2, no
significant difference in the liposome size was observed after using either a mini-extruder or a
nitrogen Lipex extruder. The mini-extruder is ideal for a sample whose volume is smaller than 1
ml. However, the optimal lipid concentration for this method was 10 mM for better size and
PDI. In comparison, the Lipex extruder could be used to prepare 1-10 ml sample in one batch
and could operate with up to 50 mM lipid concentration to achieve higher drug concentrations in
the final formulation. In addition, Lipex extrusion is the industry standard, which can be scaled
up to prepare 100-800 ml formulations by GMP standards for early clinical development. In this
project, early discovery of liposome composition employed the mini-extruders while later larger
scale liposome preparations for animal studies or formulation optimization employed a Lipex
extruder.

Table 2.2. Size, PDI and EE of DOX-loaded liposomes prepared by different extruders
Lipid Conc.
Size
Liposome
Molar Ratio Extruder
PDI. EE (%)
(mM)
(nm)
DPPC/Chol/PEG-Ceramide

10

50/45/5

Mini

110.2

0.097 65

DPPC/Chol/PEG-Ceramide

20

50/45/5

Lipex

120.4

0.086 92

2.3.3.2 Thin-film hydration versus ethanol injection. There is no qualitative difference
observed between the size of the liposomes made from the two different methods, as shown in
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Table 2.1. Generally thin-film hydration had better PDI value, which indicated better
homogeneity of the liposome system. The slight increase of PDI was probably caused by the
procedure of liposome concentration for drug loading after the diafiltration. After a composition
was selected, detailed operation procedure with higher lipid concentration was optimized.
Because ethanol injection method is more practical and commonly used in industry manufacture,
it can be scaled up for manufacturing when reproducibility of the method is established.
2.3.3.3 Manganese sulfate versus copper gluconate. There is no difference observed
between two metal salt for remote loading, as shown in Table 2.3. Because MnSO4 is not
compatible with alkaline pH and will precipitate at pH = 8.0, copper gluconate is optimal for
AZE fliposome formulation where the AZE lipid has an amine of pKa 6.8[125].

Table 2.3. Size, PDI and EE of DOX-loaded liposomes remote loading with different metal salt
Liposome

Molar Ratio

Metal Salt

Size (nm) PDI.

EE (%)

MOR-C16/DPPC/PEG-Ceramide

50/45/5

MnSO4

182.4

0.309

100

MOR-C16/DPPC/PEG-Ceramide

50/45/5

Cu-Gluconate

157.0

0.283

100

2.3.4 Characterization of calcein-loaded liposome. Calcein was utilized as a model
liposome cargo molecule to verify the release profile. All the selective liposomes had size range
140 ~ 170 nm with small PDI to indicate homogeneous liposome preparations, as shown in Table
2.4.
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Table 2.4. Size, PDI and EE of Calcein-loaded liposomes
Liposome

Molar Ratio

Size (nm)

PDI.

AZE-C16/DSPC/Chol/PEG-Ceramide

33/38/25/5

168.2

0.219

MOR-C16/DPPC/PEG-Ceramide

25/70/5

144.3

0.150

DPPC/Chol/PEG-Ceramide

55/40/5

145.4

0.088

DPPC/Chol/PEG-Ceramide

70/25/5

153.1

0.068

2.4 Summary
The pH-sensitive fliposomes were successfully prepared by thin film hydration and
ethanol injection. The traditional proton gradient or ammonium gradient method to remote load
DOX into liposomes creates acidic environment, which is not compatible with pH-senstivie
fliposomes. The metal ion remote loading method was developed to circumvent the increasing
proton concentration. Fliposomes carried high encapsulation efficiency (>80%), small mean
particle size (<200 nm) and small PDI (<0.3), indicating the robust preparation procedure. The
quality of liposomes, indicated by size, PDI, varies among different batches, suggesting that
optimization of preparation procedure is needed if fliposomes move to the step of scale-up and
manufacture.
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Chapter 3: Establishment of a Release Assay to Evaluate pH-sensitivity of Fliposome in
vitro.

3.1 Introduction
In the process of product development, the in vitro drug release from an oral dosage
form, known as dissolution testing, is an essential step to illustrate the quality of the product and
to forecast its in vivo performance [126]. Dissolution testing was first established back to 1950s
and accepted by the United States Pharmacopeia (USP) in 1970 [127]. Generally, the
formulation under the test is deposited into the apparatus and exposed to a releasing media,
ideally at sink condition. During certain time of agitation at 37°C, such as stirring of paddle or
basket, the released drug was sampled and quantified. There is also a flow-through dissolution
system known as USP apparatus 4, which is utilized to perform dissolution testing in order to fit
the requirement for sustained-release formulations. Through in vitro–in vivo
correlations/relationships (IVIVC/IVIVR), the dissolution testing could be utilized to predict the
drug candidate’s performance in vivo and served as critical data for drug development. For
instance, a highly soluble drug that was developed in an immediate release formulation could be
bio-waived because the standardized dissolution testing result is sufficient according to the FDA
regulatory guidance [126].
For complex parenteral formulations, such as liposomes and nanoparticles, the release
assay is even more important in order to achieve altered pharmacokinetics. The release assay is
widely utilized in the therapeutics of oncology. By means of nano-drug delivery system,
prolonged circulation of the drug is achieved to enhance intratumoral accumulation of
chemotherapy agent through the EPR effect. After the drug’s accumulation inside the target
tumor, its anticancer activity could be optimized by manipulating the rate of release from the
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delivery system. Therefore, the accuracy of the release assay is prerequisite to optimize the
properties of the delivery system, such as sufficient stability in circulation and quick release at
the target site.
In our lab, a release assay based on the fluorophores ANTS/DPX was used to
characterize liposomes consisting of TACH lipids and to investigate the impact of TACH lipids’
amine head groups on the liposomes’ pH sensitivity [102]. The assay mainly served as proof of
concept for the liposomes’ pH-sensitivity. For applications in drug delivery, it’s more
reasonable to evaluate the release with the cargo drug instead of ANTS/DPX. In addition, the
newly designed C16 TACH lipids have longer hydrocarbon tails and are used in liposomes in
combination with saturated phospholipids, which drastically raises the transition temperature
(Tm) of the resultant liposome formulation. Therefore, substantial changes of the release profile
and the response to lower pH are anticipated, which make it essential to develop a more reliable
release assay for DOX-loaded liposomes under this study. The aim of this chapter’s studies is to
establish reliable release assay to evaluate pH-sensitive release of fliposome in vitro.
3.2 Materials and Methods
3.2.1 Materials. Rapid Equilibrium Dialysis (RED) Device was purchased from
Thermofisher. Octaethylene glycol monododecyl ether (detergent OGME/C12E8) and Dowex®
50WX-4 were purchase from Sigma Aldrich. Acetic acid, D(+)-Glucose, 2-[4-(2hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and 2-(N-morpholino)ethanesulfonic
acid (MES) were purchased from Fisher Scientific. Doxorubicin Hydrochloride was purchased
from Biotang (Waltham, MA, USA). BioBeads SM-2 was purchased from Bio-rad (Hercules,
CA).
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3.2.2 Equilibrium microdialysis. Equilibrium microdialysis [128] by the Rapid
Equilibrium Dialysis (RED) Device (MWCO = 8,000) was utilized to establish release assay
according to the manufacturer’s recommendations. Isotonic buffers with different pH were
prepared as the following: pH 7.4 and 7.0 (100 mM HEPES, 92.6 mM glucose), pH 6.5 and 6.0
(100 mM MES, 92.6 mM glucose), pH 5.5, 5.0, 4.5 and 4.0 (100 mM acetic acid, 92.6 mM
glucose). 100 μL of Dox-loaded fliposome or non pH-sensitive liposome preparation was added
into sample chamber while 300 μL of buffer with different pHs described above was added into
the buffer chamber. The RED plate with samples were covered with sealing tape and incubated
for dialysis at 37°C at approximately 200 rpm on an orbital shaker for overnight (14 hour). An
aliquot of the solution in both sample chamber and buffer sample was taken for concentration
determination. All measurements are in triplicates. The percent of DOX released from
liposomes at different time points was calculated using the following equation.
% Dox released = [1 −

(𝐶𝑠 − 𝐶𝑏 ) × 𝑉𝑠
] × 100%
𝐶𝑖 𝑉𝑠

Where, Vs = Volume of sample chamber, Cs = concentration of Dox in sample chamber,
Cb = concentration of Dox in buffer chamber, Ci = initial liposomal Dox concentration added to
sample chamber.
3.2.3 Indirect resin adsorption method. Liposomal formulations and a buffer of
defined pH were added at v/v ratio of 1:7 into an amber glass vial. The glass vial containing the
sample was incubated at 37°C at approximately 100 rpm on an orbital shaker overnight (14
hour). 50 μL of supernatant of the releasing solution was aliquoted and transferred into a 1.5 mL
centrifuge tube filled with Dowex 50WX4 resin (Dowex : Dox = 60 : 1, wt : wt). The centrifuge
tube was agitated for 20 minutes, allowing the released doxorubicin to be completely adsorbed
by the resin. Then 10 μL supernatant was aliquoted for analysis after 2 minutes centrifuge at 200
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rpm. All measurements are in triplicate. The percent of DOX released from liposomes at
different time points was calculated using the following equation.
% Dox released =

(𝐶𝑖 𝑉𝑖 − 𝐶𝑠 𝑉𝑠 )
× 100%
𝐶𝑖 𝑉𝑖

Where, Vs = Volume of total solution after incubation, Cs = concentration of Dox of
supernatant (unreleased), Ci = initial liposomal DOX concentration added, Vi = initial volume of
liposomal DOX added.
3.2.4 Fluorescent dequenching method. In order to capture the kinetic profile of drug
release from liposomes, a more convenient and rapid release assay than Indirect Resin
Absorption is necessary. Doxorubicin has a fluorophore functional group which is excited at 490
nm and emits fluorescence at 590 nm. It is suggested that the fluorescence of doxorubicin is also
self-quenched at high concentrations because of the large overlap between the absorption and the
emission spectra [129, 130]. Therefore, doxorubicin release could be reflected by the
dequeching of its fluorescence as the molecules move from its high concentration inside the
liposome to low concentration outside.
Each liposomal sample (2 μL) was added into 198 μL of different buffer in a black 96
well plate. The fluorescent measurement of doxorubicin as the baseline of no release was
recorded by the Synergy HT microplate reader (Biotek, Winooski, VT, USA) at 485 nm
(excitation) and 590 nm (emission) promptly after sample addition. The plate was sealed with
tape and incubated at 37 °C on an orbital shaker at approximately 100 rpm. At incremental time
points (1, 3, 6, 12, 24, 48 h), the fluorescent intensity of each sample was measured. At the end
of experiment, 10 µl detergent (C12E8) was added to fully lyse the Dox-loaded liposomes to
obtain the fluorescent intensity of complete release (Fx-100). The release percentage was
calculated as following,
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% Dox released =

𝐹𝑡 − 𝐹0
x 100%
𝐹𝑥−100 − 𝐹0

Where Ft is the fluorescence intensity of a given time point and F0 is the baseline
fluorescence intensity upon sample addition, Fx-100 is the fluorescence intensity of liposome that
is 100% lysed.
3.2.5 Direct resin adsorption method. Dowex 50WX4 resin or Bio-beads resin was
mixed with a buffer-diluted sample of liposomal doxorubicin in an amber glass vial at the ratio
of resin : Dox = 200 : 1 or 1000:1 (wt : wt), respectively. The mixture was incubated at 37°C on
an orbital shaker at approximately 100 rpm. At incremental time points (0, 3, 6, 12, 24, 36, 48
h), 10 µl supernatant of each sample was aliquoted and transferred into 90 µl lysing buffer (90%
isopropanol containing 0.075 M HCl) to quantify DOX. All measurements were in triplicates.
The percentage of DOX released from liposomes at different time points was calculated using
the following equation.
% Dox released = (1 −

𝐶𝑠 𝑉𝑠
) × 100%
𝐶𝑖 𝑉𝑖

Where, Vs = Volume of total solution after incubation, Cs = concentration of Dox of
supernatant (unreleased), Ci = initial liposomal DOX concentration added, Vi = initial volume of
liposomal DOX added.
3.2.6 pH-Triggered release of calcein-loaded fliposmes. Each sample (20 µl) of
calcein-loaded liposomes was added into 180 µl of different pH buffer solutions (defined in
Section 3.2.2) in a black 96 well plate. The plate was covered with sealing tape and incubated at
37°C on an orbital shaker at approximately 100 rpm. At different time points (0, 1, 2, 4, 6, 9, 12,
24, 36, 48 h), the fluorescence of each well was measured on the Synergy HT microplate reader
(Biotek, Winooski, VT, USA) (Ex. = 495 nm and Em. = 515 nm). At the end of experiment,
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10 µl detergent (C12E8) was added to completely disrupt the bilayer of liposomes and release
calcein for the 100% release measurement. All measurements are in triplicate. The release
percentage was calculated as following,
Dox released =

𝐹𝑡 − 𝐹0
x 100%
𝐹𝑥−100 − 𝐹0

Where Ft is the fluorescence intensity of a given time point and F0 is the fluorescence
intensity of initial time point upon sample additiion, Fx-100 is the fluorescence intensity of
liposome that was 100% lysed.
3.3 Results and Discussion
3.3.1 Equilibrium microdialysis. Selected liposome formulations (DPPC:PEG-DPPE =
95:5, MOR-C16:DPPC:PEG-DPPE = 25:75:5, AZE-C16:DPPC:PEG-DPPE = 25:75:5) were
utilized to establish and validated this release assay. The percentage of pH-triggered release of
liposomes at four different pH was shown in Table 3.1.

Table 3.1. Release percentage of selected DOX-loaded liposomes by Equilibrium Microdialysis
pH
DPPC
MOR-C16
AZE-C16
6.0
6.5
7.0
7.4

41.33
36.24
36.83
16.45

37.30
28.32
10.36
26.16

47.09
33.62
40.40
40.78

All selected liposomes showed certain extent of pH-sensitivity by exhibiting elevated
release at lower pH. In the meantime, the equilibrium of release could be achieved even within 2
hours with increased rpm for shaking. However, large amount of red stains was observed on the
dialysis membrane, which indicated remarkable mass loss during the dialysis process. The
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average recovery rate among all sample is ~ 72.2%. Furthermore, recovery rate of free
doxorubicin at concentration 250 μg/ml, 500 μg/ml and 1000 μg/ml was 16.17%, 26.31% and
33.87% respectively following the same procedure with pH 7.4 buffer. This phenomenon could
be explained by the interaction between positive charged doxorubicin and cellulose membrane of
dialysis tube [131]. Therefore, equilibrium microdialysis was not appropriate for release assay
of doxorubicin.
3.2.2 Indirect resin adsorption method. Select liposomes with different compositions
Tach-C16:DPPC:PEG-DPPE = 25:75:5) were utilized to establish and validate this release assay.
The percentage of pH-triggered release of liposomes at defined pH after 14 hour incubation at 37
°C is shown in the Figure 3.1. Among all pH-sensitive lipids, MOR-C16 showed the largest
difference in leakage between physiological environment (pH 7.4) and tumor microenvironment
(pH 6.0), which made it one of our leading TACH lipids for further investigation. In addition,
AZE-C16 has a pKa value around 6.8, which encouraged us to further investigate the lipid for
quick response to drop of pH.
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Figure 3.1. Release Percentage of DOX-loaded fliposomes over 14h at defined pHs, 37°C by
Indirect Resin adsorption methods. Data presented as mean ±SD, N = 3.

Dowex 50WX4 is a strong cation-exchange resin which could adsorb positively charged
doxorubicin upon their release from liposomes. Therefore, Dowex 50WX4 is used to remove
residual free doxorubicin after active loading of liposomes [132]. For liposome release assay,
the aqueous solution in the vial is a mixture of released free doxorubicin and unreleased
doxorubicin entrapped inside of liposome after incubation. When the mixture solution was then
agitated with Dowex resin, the released, free doxorubicin would be adsorbed by resin, thus
allowing the measurement of doxorubicin still trapped in the liposome formulation. Because the
fliposomes are typically neutrally charged and have a size (~100 nm) much larger than the pores
on the resins (~ 10 nm), the resins would not significantly influence the release of the liposomes
by directly interacting with them. However, the drawback of this method includes its tedious
procedure to recover the formulation with the unreleased doxorubicin and its inability to recover
the whole mass balance.
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3.2.3 Fluorescent dequenching method. Selected liposomes with different
compositions were utilized to establish and validate this release assay. The kinetics of pHtriggered release of liposomes at defined pH over 48 hour incubation at 37 °C was tracked and is
shown in the Figure 3.2. The pH-sensitive liposomes (MOR-C16:DSPC:Chol:PEGCeramide=30:40:25:5) showed different release profile depending on the pH while the
conventional liposome (DPPC:Chol:PEG-Ceramide= 50:45:5) maintained the same pattern of
leakage at all pHs from 4.0 to 7.4. However, we observed the controversial response to lowered
pH at two different pH ranges. As shown in Figure 3.2 over 48 hours and Figure 3.3 at 24 hour,
fliposome had more leakage at more acidic pH range from 4.0 to 5.5. However, the trend was
reversed at pH range from 6.0 to 7.4.
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Figure 3.2. Release Percentage of DOX-loaded liposomes (Left: pH-sensitive fliposome MORC16:DSPC:Chol:PEG-Ceramide=30:40:25:5, Right: pH-insensitive liposome DPPC:Chol:PEGCeramide= 50:45:5) over 48h at defined pHs, 37°C by Fluorescent dequenching methods. Data
presented as mean ±SD, N = 3.
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Figure 3.3. Release Percentage of DOX-loaded fliposomes (MOR-C16:DSPC:Chol:PEGCeramide=30:40:25:5) at 24h at defined pHs, 37°C by Fluorescent dequenching methods. Data
presented as mean ±SD, N = 3.

It was reported that Doxorubicin is not stable at neutral pH, 37°C, with a degradation rate
constant of 0.0174 (1/hour) [131]. The degradation rate decreases as the pH of the buffer
decreases. The remaining percentage of doxorubicin (125 µg/ml) after incubation at four pHs,
37 °C in our experiments conformed with the literature (Table 3.2). Therefore, the released
doxorubicin will gradually degrade over the whole process to cause an underestimation of the
complete release (Fx-100), the more close to 7.4, the more the underestimation. All these findings
suggested the limitation of the florescent dequenching method to evaluate release in response to
different pHs, even though it was the most convenient method to obtain kinetic release profile of
liposomes if artefacts from the degradation can be mitigated.

Table 3.2. Doxorubicin remaining in solution at 37°C over 12 h at pH 6.0, 6.5, 7.0 and 7.4 (n =
3).
pH
7.4
7.0
6.5
6.0
Remain %

68.82±1.47

76.94±2.10

89.98±8.35

94.57±3.06
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3.2.4 Direct resin adsorption methods. Direct resin adsorption was optimized in order
to precisely obtain the kinetic release profile of the DOX-loaded liposomes. The advantage of
this method is that it balances the ease of the operation procedure and the accuracy of the assay.
The percentage of pH-triggered release of liposomes (Table 3.3) at defined pHs over 48 hour
incubation at 37 °C was tracked and shown in the Figure 3.4. The pH-sensitive liposomes with
AZE-C16 gave the most response upon the drop of pH, while those with MOR-C16 had less
change of the release percentage. The conventional liposome showed no difference of release
among all pH from 4.5 to 7.4.

Table 3.3. Composition and characterization of selected DOX-loaded liposomes for direct resin
adsorption method
Liposome

Mole ratio

Size (nm)

PDI.

AZE : Chol : PEG-Ceramide

50:45:5

301.8

0.377

MOR : Chol : PEG-Ceramide

50:45:5

258.8

0.347

DPPC : Chol : PEG-Ceramide

50:45:5

112.6

0.122
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Figure 3.4. Release Percentage of DOX-loaded fliposomes over 48 h at defined pHs, 37°C by
Direct Resin adsorption methods.
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Dowex 50WX4 is a strong cation-exchange resin which can adsorb free, positively
charged doxorubicin. Bio-Beads SM-2 Resin is composed of neutral, macroporous polystyrene
beads which are widely used as adsorbent in hydrophobic interaction chromatography. The
aromatic rings of doxorubicin could interact with those nonpolar polymeric beads, leading to the
adsorption. Both of resins have the pore size below 10 nm, allowing doxorubicin molecules to
be trapped inside for adsorption. The fliposomes are typically composed of neutral lipids and
larger than 100 nm in diameter so the interference by resin on the fliposome release could be
considered insignificant. Therefore, the direct resin adsorption method would be an acceptable
method, by which the release profile would be correctly monitored and the procedure would be
practical to run large numbers of samples. However, the drawback of this method was the
inability to recover the whole mass balance due to practical feasibility.
3.2.5 pH-Triggered release of calcein-loaded fliposmes. In order to validate the release
profile of DOX-loaded fliposomes, we studied the pH-dependent leakage of fliposomes by
measuring their release of a self-quenching fluorophore, Calcein at pHs 7.4, 7.0, 6.5 and 6.0,
37°C over time. The fluorescence of Calcein was measured and then normalized against the
fluorescence of the lysed liposome sample after adding detergent. The pH-triggered release of
calcein over 48 hours from select calcein-loaded fliposomes are shown in Figure 3.5. The
fliposomes exhibited increased release at lower pH, while the conventional liposome maintained
the similar release profile regardless of pH. The DOX-loaded and calcein-loaded fliposomes
demonstrated the same the pH-sensitivity trends as shown in Figure 3.6.
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Figure 3.5. Release Percentage of calcein-loaded liposomes over 48h at defined pHs, 37°C
(n=3).
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Figure 3.6. Release Percentage of DOX-loaded fliposomes and calcein-loaded fliposome after
12h at defined pHs, 37°C. Data presented as mean ±SD, N = 3.

Calcein, also known as fluorexon, is a widely used fluorescent probe in cell imaging by
fluorescent microscopy [133]. Calcein is excited at 495 nm and emits at 515 nm. Calcein is
highly water soluble and its fluorescence self-quenches when the concentration reaches above 70
mM (Figure 3.7), consistent to the literature report [134]. Therefore, calcein has been
prominently utilized as a model probe for investigating drug release from liposomes and
liposome-drug interaction. Generally, calcein, at the concentration above the self-quenching
concentration, is entrapped inside the aqueous core of liposome by passive loading during
hydration. When calcein is release from liposome, it is diluted to give de-quenched and thus
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elevated fluorescent signal. Therefore, it is an excellent model to validate our doxorubicin
release assay on different fliposomes. Besides calcein, fluorescent dye-and-quencher pairs, such
as ANTS/DPX are also used in fluorescent assays on the release of liposomes [108, 135].
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Figure 3.7. Fluorescence intensity vs calcein concentration profile.

3.4 Summary
We have studied several release assays for DOX-loaded liposomes, including traditional
dialysis methods, fluorescent methods and our new resin adsorption methods. Because of the
unique chemical properties of the cargo drug, doxorubicin, it is hard to find a direct method to
measure the released drug in sink condition, which is recognized as the golden standard in
industry. Despite certain drawbacks such as the potential interaction between resin and
formulation and the lack of mass balance, the direct resin adsorption method appears to be the
most practical and feasible method to kinetically monitor the release profile of pH-sensitive
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liposomes in vitro. The advantage and disadvantage of the four release assay methods is
summarized in Table 3.4.

Table 3.4. Comparison of release assay methods
Method

Pros

Cons

Equilibrium microdialysis

•
•

Quick
Small sample sizes

•

Low recovery

Indirect Resin adsorption

•

Higher accuracy

•
•

Fluorescent dequenching

•

High throughput

•

Complicated process
Systemic error from
sample size
Degradation

Direct Resin adsorption

•
•

Acceptable error
Kinetic monitoring

•

Possible interaction
between resin and
liposome
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Chapter 4: Optimization of pH-sensitive Fliposomes

4.1 Introduction
In order to maximize the benefit of liposomes for anticancer therapy, many properties of
such systems need to be optimized. In addition to triggered release, which is a focus for this
dissertation, stability, small and homogeneous size, and adequate drug-loading capacity are all
important properties of liposomes for anticancer therapy.
Particle size is an essential characteristic of nano drug delivery systems. The size is
directly associated with stability, drug payload, release profile as well as pharmacokinetics of the
drug delivery system [136]. Most importantly, an appropriate size range will allow the
liposomes to extravasate from blood circulation into the tumor by the EPR effect, but not to be
cleared by the body [120, 122]. As a reference, market product Doxil® has a size range of 80 100 nm [38]. It would be critical to include particle size as a parameter for optimization.
Polydispersity Index (PDI) is the term to describe the degree of heterogeneity in the size
distribution of a nanoparticle sample [136, 137]. The value of PDI ranges from 0.0, which
represents a perfectly uniform sample, to 1.0, which represent a total random distribution of the
particle size. PDI values of 0.3 and below are typically accepted to indicate a nanoparticle
formulation of reasonable quality [137]. From the perspective of liposomes for drug delivery,
many efficiency and safety issues are related to the size of liposome, such as premature leakage.
Successful liposome preparations, therefore, should contain homogenous populations of
nanometer-range vesicle of an optimal size. The uniformity is another desirable attribute of the
fliposomes for further application.
pH-sensitivity and stability are two diagonally opposite properties for quality control.
Stability is the fundamental requirement for the design of nano-formulations because it prevents
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many toxicity issues and allows the accumulation of the delivery system at the target site. It was
reported that 24-hour circulation is required for the manifestation of the EPR effect [138]. On
the other hand, pH-sensitivity enables the nano-formulation to respond to the acidic tumor
microenvironment, pH 6.0. Balancing the two opposing properties of the fliposomes is the focus
of this Chapter.
Drug-loading capacity is an easily overlooked but important property of a formulation.
The application of any drug formulation requires a minimum loading capacity to eventually
deliver enough treatment agent. In our case, it can be optimized to prepare formulation of
sufficient amount and concentration for the animal studies. The reference of 2 mg/ml
doxorubicin concentration in Doxil® is selected as our target.
The manufacture procedure can be modified to improve the above-mentioned properties.
Dispersion techniques, such as sonication and extrusion, could be options to optimize the
preparation. Lipid-to-drug ratio was also reported to be a key parameter to increase the
concentration of the drug payload [139]. Lipid composition is the focus of this study to optimize
the formulation for in vitro and in vivo studies. The aim of this chapter’s studies is to identify the
factors influencing the outcomes of EPR effect and to optimize the formulation using
comprehensive method.
4.2 Materials and Methods
4.2.1 Materials. The lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC), N-palmitoyl-sphingosine-1(succinyl[methoxy(polyethylene glycol)2000]) (PEG-ceramide (2000)), 1,2-dipalmitoyl-snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)) were
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Cholesterol, copper(II) D-
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gluconate, Dowex® 50WX-4, 2-Amino-2-(hydroxymethyl)propane-1,3-diol (Tris) and
triethanolamine (TEA) were purchased from Sigma-Aldrich. Doxorubicin Hydrochloride was
purchased from Biotang (Waltham, MA, USA).
4.2.2 Screening design for identification primary factors. Various liposomes with
different lipid compositions were prepared by the thin-film hydration methods listed in 2.2.2.1.
The size and -potential of the liposomes were characterized by the methods listed in 2.2.4. The
DOX concentration and drug encapsulation efficiency were determined by the methods listed in
2.2.5. pH-sensitivity and stability were evaluated by the direct resin adsorption release assay
listed in 3.2.5. The primary factors that control the system were identified by the evaluation of
colloidal stability and the pH-sensitivity with liposome charaterization.
4.2.3 Response surface methodology (RSM) for fliposome optimization. Central
composite design (CCD) experiments were conducted to visualize the effects of independent
variables on the select responses which represent the desired properties of the fliposomes. Two
variables, percentage of Tach lipid and cholesterol, were identified as major independent factors
through screening design and used in the design of the experiments by RSM. Five responses,
size, PDI, pH-sensitivity, stability and maximum drug loading were selected to represent the
desired properties of fliposomes, where pH-sensitivity was defined as equation below,
𝑝𝐻 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (%) = 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 % 𝑎𝑡 𝑝𝐻 6.0 − 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 % 𝑎𝑡 𝑝𝐻 7.4
after 48 hours; stability was defined as released DOX% at pH 7.4 after 48 hours.
CCD by 2 factors and 5 central points consisted of 13 runs with alpha level (α = 2k/4, k=
number of factors) at 1.414 for two independent variables. The ranges and level of the variables
are listed in Table 4.1. The complete CCD design matrix of experiments and the responses from
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a total of 13 experiments were presented in the Table 4.6. CCD and response surface diagram
were constructed using Design-Expert (7.0.0) software.

Table 4.1. Factors and the correspondent values in coded and physical form
Levels
Factors
Code
-α
-1
0
+1
AZE%
X1
25%
28.66%
37.5%
46.34%
Chol%
X2
20%
23.66%
32.5%
41.34%

+α
50%
45%

All runs in CCD experiments were prepared by ethanol injection methods listed in
2.2.2.2. The liposomes were characterized by the methods listed in 2.2.4 while doxorubicin
concentration and drug encapsulation efficiency were determined by the methods listed in 2.2.5.
pH-sensitivity and stability were evaluated by direct resin adsorption release assays listed in
3.2.5.
4.2.4 Prediction by RSM. The optimal factor level as reflected by the AZE-C16 and
cholesterol molar percentage in the composition was predicted by Design-Expert (7.0.0) software
(Stat-Ease, Minneapolis, MN). The criteria of independent factors and response were listed in
Table 4.2. Point prediction was conducted with numerical solutions function.
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Table 4.2. Optimization criteria for AZE-C16 based flipsomes
Lower
Lower
Factors
Goal
Upper limit
limit
weight
AZE%
In range
10
60
1
Chol%
In range
20
40
1
Size
Minimize
100
300
1
PDI
Minimize
0.1
1
1
pH
Maximize
0
40
sensitivity
Stability
Minimize
0
50
1
Drug
Maximize
1
2
loading

Upper
weight
1
1
-

Importance
+++
++++

1

+++++

-

++++

1

+++

4.2.5 Data analysis. Data are presented as mean ±standard deviation (SD) for the
screening design study. The statistical analysis was performed by t-test for the pegylated lipid
composition study using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA).
Model selection and analysis of variance (ANOVA) for select model were performed using
Design-Expert 7.00 Software (Stat-Ease, Minneapolis, MN). The results with p < 0.05 were
accepted as statistically significant. Response surface plot and contour plot was generated by
Design-Expert (7.00) Software.
4.3 Results and Discussion
4.3.1 Effect of pegylated lipid composition. The effect of pegylated lipid in the bilayer
of liposomes on the size, PDI, drug loading and pH-sensitivity was evaluated with the select
compositions listed in Table 4.3. The fliposomes with two different pegylated lipids didn’t show
much change on the size, PDI, drug loading capacity, as suggested in Table 4.3. A slight
increase of size was observed with the fliposomes prepared with PEG-ceramide, which is a
potential reason for the small increase of drug loading. Both fliposomes have similar PDI values
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around 0.2, suggesting homogenous size distribution of the colloid system. Apparently,
significant difference in pH-sensitivity was observed between the two pegylated lipids. In Figure
4.1, the fliposome with PEG-ceramide released 16% more than the one with PEG-DPPE after 24
hour incubation at 37°C. This drastic increase could be contributed by the charge of pegylated
lipid molecule. PEG-Ceramide is neutral while PEG-DPPE is negatively charged. When the
fliposome was exposed to the environment of lower pH, those negative charged phosphate group
in PEG-DPPE would compete with TACH lipid to grab proton. Because there was 5% such
molecules in the bilayer, the pH-sensitivity would be counterbalanced. This observation was
also explained by potential ionic interaction between the phosphate group of DSPE-PEG and the
protonated amine group in TACH C12 lipid [102], which is thought to compete with the
formation of an intramolecular hydrogen bond by the TACH lipid. Therefore, PEG-ceramide
was chosen over PEG-DPPE for further investigation of liposomes.

Table 4.3. Composition, size, PDI, EE and drug loading concentration of select DOX-loaded
fliposomes with two pegylated lipid
Liposome

Mole
ratio

Mor-C16 : DPPC : PEG-DPPE

50 : 45 : 5 158.8

Mor-C16 : DPPC : PEG-Ceramide

50 : 45 : 5 180.1

EE
(%)

Dox Conc.
(mg/ml)

0.177

71.70

0.717

0.208

82.57

0.826

Size (nm) PDI.
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Figure 4.1. Pegylated lipid effect on release profile of DOX-loaded fliposomes at pH 6.0, 37°C
after 24 hours. Data presented as mean ±SD, N = 3. *** p<0.001 for t-test.

4.3.2 Effect of cholesterol. The effect of cholesterol in the bilayer of liposomes on the
size, PDI, drug loading and pH-sensitivity is evaluated with the select composition listed in
Table 4.4. The liposomes with and without cholesterol in composition were characterized and
result was listed in Table 4.4. Without cholesterol in the bilayer of liposomes, the size and PDI
were larger than the liposomes with cholesterol. In addition, it was prominent that the drug
loading was higher after adding cholesterol into the bilayer for the non-pH sensitive liposomes.
Cholesterol also increased the stability of the liposomes, as indicated by the lower release of nonpH-sensitive liposomes at all pHs ranging from 6.0 to 7.4 (Figure 4.2).

Table 4.4. Composition, size, PDI, EE and drug concentration of DOX-loaded liposomes with
and without cholesterol
EE
Dox Conc.
Liposome
Mole ratio Size (nm) PDI.
(%)
(mg/ml)
DPPC : PEG-DPPE

95 : 5

219.4

0.474

36.6

0.366

DPPC : Chol : PEG-DPPE

70 : 25 : 5

188.8

0.120

79.4

0.794
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Figure 4.2. Cholesterol effect on release profile of DOX-loaded liposomes (DPPC : PEGDPPE= 95 : 5, DPPC : Chol : PEG-DPPE = 70 : 25 : 5) at defined pHs, 37°C after 24 hours.
Data presented as mean ±SD, N = 3.

It was reported that cholesterol can stabilize liposomal formulation when added into the
bilayer structure [140, 141]. It was found that cholesterol controlled the fluidity of the liposome
bilayer by occupying the cavities between the hydrocarbon chains of phospholipid, thereby
inhibiting the free movement of those fatty acyl chains in the dispersed liquid crystalline phase
[142]. In the gel phase, cholesterol can disturb the crystalline chain lattice in the bilayer, thereby
increasing the permeability of the liposome [143]. Therefore, cholesterol would augment the
liposome stability when the temperature is elevated above the transition temperature (T > Tm)
and would enhance the drug retention during the high temperature of incubation. However, the
incorporation of cholesterol would also decrease the pH-sensitivity because the fliposomes are
exposed to the physiological temperature around 37°C in vivo, which is below their transition
temperature. In addition, it has been reported that the higher ratio of cholesterol to DPPC (0.8 ~
1.0) in the liposome bilayer will form an extraordinary lateral order, which is an extremely stable
system without noticeable transition temperature [142].
With those prominent influences on the physicochemical properties and on the pHsensitivity, cholesterol was chosen as primary factor for the further optimization.
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4.3.3 Effect of phospholipid. The effect of phospholipid in the bilayer of liposomes on
the size, PDI, release profile was evaluated with the select compositions listed in Table 4.5. The
liposomes that were prepared with DPPC didn’t show any significant difference with those with
DSPC in the physicochemical properties, such as size and PDI, however, lower drug release, no
matter within conventional liposomes or fliposomes, was observed in the presence of DSPC.

Table 4.5. Composition, size, PDI and release percentage of DOX-loaded liposomes with
different phospholipids (n=3).
Release% after
Liposome
Molar ratio
Size (nm) PDI
pH
12 hr
DSPC : Chol :PEG70:25:5
134.3
0.093
6.5
41.5±1.6
Ceramide
DPPC : Chol :PEG70:25:5
116.4
0.046
6.5
58.9±1.6
Ceramide
DSPC : Mor-C16 : PEG70:25:5
122.1
0.084
7.4
42.2+1.0
Ceramide
DPPC : Mor-C16 : PEG70:25:5
108.4
0.109
7.4
66.6±0.4
Ceramide

It was well acknowledged that the transition temperature (Tm) of a liposome system is
mainly determined by the Tm of the component lipids. Tm is defined as the temperature at which
the lipid bilayer has a physical change from the ordered gel phase to the disordered liquid
crystalline phase[144]. The hydrocarbon length of the lipid tail and saturation/unsaturation of
the fatty acyl chains of the lipids are the two main factors that determine the Tm. In Table 4.6,
five different phospholipids with different Tm are listed. It was also reported that an increase in
length of the hydrocarbon chain (and therefore transition temperature) is directly correlated to
stability[145]. Therefore, incorporating DSPC or DPPC into the liposome bilayer to balance the
stability and pH-sensitivity is considered as a key factor for further optimization.
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Table 4.6. Transition Temperature of Phospholipids[146]
Hydrocarbon
Unsaturated
Lipid
length
bond
DLPC
12
0
DMPC
14
0
DPPC
16
0
DSPC
18
0
DOPC
18
1

Tm (°C)
-1
23
41
55
-20

4.3.4 Effect of flipids. The effect of flipid in the bilayer of liposomes on the size, PDI
and pH-sensitivity was evaluated with the select composition listed in Table 4.7 and 4.8.
Increase in size and PDI was observed along with an increase of molar percentage of flipids in
the fliposome composition (Table 4.7). It was also accompanied by the drastic increase in the
resistance during the extrusion. The PDI value was above 0.3, suggesting that the colloidal
system was not stable, and/or that a large aggregation was forming. Together these phenomena
indicated that TACH lipids were not compatible with the liposomal bilayer structure at high mole
percentages. This may be caused by the steric hindrance of the amine head group as well as the
cyclohexanol ring (Figure. 4.3). In addition, the close-to-zero surface charge of the liposomes
may also contribute to the aggregation. On the other hand, a flipid was introduced to render the
saturated and PEGylated liposomes pH-sensitive. It was apparent that the pH-sensitivity in this
case, which is the difference between the release percentage at physiological pH 7.4 and tumor
microenvironment pH 6.0, will be boosted with increasing flipid composition. It is demonstrated
by the comparison in Table 4.8 that doubling the molar percentage of MOR-C16 lead to nearly
18% raise of the pH-triggered release.
Given the different effects of the flipid as discussed above, it is crucial to optimize the
molar percentage of flipid to balance between pH-sensitivity and good colloidal properties of the
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liposome. Therefore, mole percentage of flipid was selected as another primary variable for
further optimization.

Table 4.7. Composition, size, PDI of empty fliposomes of different mole percentage of the
Tach-lipid.
Liposome
Molar ratio
size (nm)
PDI
DPPC : MOR-C16 :PEG-Ceramide
DPPC : MOR-C16 :PEG-Ceramide
DPPC : MOR-C16 :PEG-Ceramide

65:30:5
55:40:5
45:50:5

116.7
179.3
221

0.169
0.459
0.569

Table 4.8. Composition, size, PDI and release percentage of DOX-loaded fliposomes at different
mole percentage of the TACH-lipid MOR (n=3).
Release %
Liposome
Molar ratio Size (nm) PDI pH sensitivity %
after 48 hr
DPPC : MOR-C16 :PEG70 : 25 : 5
108.4
0.109 15.9±1.2
64.0±4.4
Ceramide
DPPC : MOR-C16 :PEG45 : 50 : 5
182.4
0.309 34.1±3.4
94.3±1.8
Ceramide
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4.3.5 Optimization of liposome composition with response surface methodology
(RSM). Based on the RSM approach, the total number of runs was calculated as 2k + na + n0,
where k is the number of independent factors, 2k represents the full factorial design points, na
represents the axial points determined by α level, and n0 is the replicate number of center point.
In this experiment, we had 2 factors, and 5 central points to give 13 total runs.
A general equation for the relation of independent variable and response is:
Y=b0＋b1X1+b2X2+b3X1X2+b4X12+b5X22.
Where Y is the dependent variable; X1 and X2 are the independent variables; b0 is the
intercept coefficient, which is the model constant; b1 and b2 are the estimated linear coefficients
for the factor X1 and X2 respectively; b3 is interaction coefficient and b4 and b5 are quadratic
coefficients. The magnitude and the mathematical sign of coefficients suggested the degree of
effect upon the dependent responses. The complete CCD design matrix of experiments and the
responses from a total of 13 experiments were presented in the Table 4.9.
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Table 4.9. CCD of experiments for optimization of AZE-C16 based fliposome utilizing DX-7
software.
Run X1
X2
size
pH sensitivity
Stability Drug loading
PDI
No. (AZE%)
(Chol%) (nm)
(%)
(%)
(mg/ml)
1

37.50

32.50

178.1

0.279

28.05

34.63

1.42

2

28.66

41.34

173.3

0.255

15.70

27.63

1.73

3

37.50

45.00

283.2

0.515

8.43

48.87

1.51

4

46.34

41.34

187.9

0.328

8.64

44.04

1.42

5

37.50

32.50

258.5

0.606

7.53

46.27

1.47

6

37.50

32.50

212

0.359

17.15

48.89

1.10

7

37.50

32.50

163.5

0.198

24.33

44.20

1.60

8

46.34

23.66

228.7

0.575

18.00

51.38

1.30

9

37.50

20.00

158.8

0.173

10.73

43.40

1.85

10

50.00

32.50

175.8

0.195

12.90

42.71

1.13

11

37.50

32.50

166.6

0.316

21.68

48.07

1.26

12

28.66

23.66

139.9

0.308

13.63

46.71

1.42

13

25.00

32.50

146.3

0.31

4.72

49.27

1.08

Table 4.10. Coefficients of regression equations for the responses with actual factors
Dependent variable
(Reponses)

Regression coefficients

Size (nm)

b0
-90.44

b1
16.56

b2
-7.77

b3
-0.237

b4
-0.090

b5
0.293

PDI

-

-

-

-

-

-

pH sensitivity (%)

-181.0

6.29

5.21

-0.037

-0.066

-0.061

Stability (%)

-

-

-

-

-

Drug loading (mg/ml)

2.017

0.097

-0.148

-6.01E4

-1.10E-3

2.61E-3

According to the ANOVA test of model on all five dependent variables, none of them
statistically fit to a quadratic model. Only size, pH-sensitivity and drug loading were suggested
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by lack of fit tests to fit as a quadratic model, and the coefficients of general regression equations
for the actual factors were listed in Table 4.10. Although the fitting was not good to have
regression, the effect of two primary factors on key properties of the AZE-C16-based fliposome
was still able to be evaluated.
4.3.5.1 Effect of AZE-C16 and cholesterol percentage on size. In order to fully utilize
the EPR effect, size is the critical parameter which need to be well controlled during the
preparation procedure. For the simplicity procedure, the extrusion of all fliposome in 13 runs
were only conducted through 200 nm polycarbonate filters 5 times for the sake of the
productivity. Therefore, all the sizes of fliposomes wouldn’t be close to 100 nm. For the
optimization purpose, it was one factor to reflect good quality of a colloidal system. It was
apparent that the size increased along with the increase of AZE% and Chol%. It could also be
reflected by the trends in response surface plot (Figure 4.4) and quadratic equation: size = -90.44
+ 16.56 * AZE% - 7.77 * Chol% - 0.237 * AZE% * Chol% - 0.090 * (AZE%)2 + 0.293*
(Chol%)2.
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Figure 4.4. Response surface plot (3D) (left) and contour plot (right) showing the effect of
AZE% and Chol% on Size.
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4.3.5.2 Effect of AZE-C16 and cholesterol percentage on pH sensitivity. Rendering pHsensitivity is our main approach to improve pegylated liposomes. According to the 3D response
surface plot (Figure 4.5), the pH-sensitivity increased with the increase of AZE% or Chol% to
certain extent, then the pH-sensitivity gradually decreases. It was reflected by larger values in
the central concentric circle of the contour plot. The quadratic equation was pH sensitivity = 181.0 + 6.29 * AZE% + 5.21 * Chol% - 0.037 * AZE% * Chol% - 0.066 * (AZE%)2 - 0.061*
(Chol%)2. Mathematically, after AZE% and Chol% went over certain value, the negative effect
from the quadratic parts of the equation would counterbalance the positive contribution from the
linear parts.
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Figure 4.5. Response surface plot (3D) (Left) and contour plot (Right) showing the effect of
AZE% and Chol% on pH sensitivity.

4.3.5.3 Effect of AZE-C16 and cholesterol percentage on drug loading. Drug loading
was an important response of RSM we would like to look into because of the needs of the animal
studies. Higher loading gave more flexibility to conduct animal experiments. The market
product Doxil® is at 2 mg/ml doxorubicin concentration, therefore, the aim of our fliposome was
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to get close to 2 mg/ml at non-optimized condition. Among three of the quadratic models, drug
loading was least significant relative to the noise. According to the equation from the modeling,
Drug loading = 2.017+ 0.097 * AZE% - 0.148 * Chol% - 6.01E-4 * AZE% * Chol% - 1.10E-3 *
(AZE%)2 + 2.61E-3 * (Chol%)2, where the intrinsic drug loading is close to 2 mg/ml at our
current lipid to drug ratio (4:1, wt : wt). The contribution from lipid composition was limited,
while the drug-loading would decrease along with more cholesterol in the liposome bilayer
(Figure 4.6). It can be easily explained by the fact that cholesterol by itself is not conducive to
the formation of the lipid bilayer, and thus would decrease the total number of liposome vehicles
available for drug loading with the increase of its molar ratio.
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Figure 4.6. Response surface plot (3D) (Left) and contour plot (Right) showing the effect of
AZE% and Chol% on Drug loading.

4.3.5.4 Prediction of AZE-C16 based fliposome by RSM optimization. Based on the
constraints of the criteria set up, 30 starting points were simulated by Design-Expert. One
numerically optimized solution with the constraints of AZE% & Chol% in range and five
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responses in target was obtained, of which the lipid composition is AZE: DSPC: Chol: PEGCeramide = 38: 32: 25: 5. The predict response is listed in Table 4.11.

Table 4.11. Predition of AZE-C16 based fliposome by RSM optimization
Response

Size
(nm)

PDI

pH sensitivity Stability
(%)
(%)

Drug loading
(mg/ml)

Prediction

171.00

0.292

19.19

1.47

44.37

4.4 Summary
Several factors in the preparation of liposome formulation were investigated. The
Neutral pegylated lipid, PEG-Ceramide was chosen for enhanced pH-sensitivity. Cholesterol
and DSPC were necessary for the stability of the liposomes, including the AZE-C16-based
fliposomes of quick response. RSM was utilized to further optimize the AZE-C16 based
fliposome. AZE: DSPC: Chol: PEG-Ceramide = 38: 32: 25: 5 was predicted by RSM to have
relatively high stability and pH-sensitivity. The optimized formulation was brought for further
biological evaluation of efficacy together with another fliposome formulation MOR-C16: DPPC:
PEG-Ceramide = 70: 25: 5, which had been previously identified in previous work [104].
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Chapter 5: Evaluation of Anticancer Efficacy of Doxorubicin-loaded Fliposome in vitro

5.1 Introduction
The main stream strategy in the pharmaceutical industry to screen anticancer drugs and to
validate their activities is to use two-dimensional models of cultured cells in vitro and animal
models in vivo. Although in vitro 2D monolayer cell culture has many advantages such as
convenience, high throughput and low-cost, their main drawback is the lack of cell-cell and cellmatrix interactions. In addition, although solid tumors usually carry variations in oxygen level,
metabolite concentration and acidic extracellular pH, such features are all missing in 2D cell
culture models [147]. More and more studies have discovered the poor correlation between the
monolayer cell models in vitro and the animal models in vivo, which would explain the gap
between findings at early stages of drug screening and late stages of drug development.
Therefore, there is a great demand of cost-efficient and accurate in vitro models to bridge such a
gap, especially in oncology.
3D MCS were established in the 1970s by Sutherland et al [148], and have now
demonstrated many advantages over 2D cell culture models. 3D MCS are self-assembled under
conditions that allow cells to grow and interact with their surroundings in three dimensions. A
necrotic core can be observed in MCS when the size reaches 500 µm. The necrotic core is
surrounded by a proliferative zone and a quiescent zone [149]. A typical configuration of 3D
MCS (> 500 µm) with different areas is shown in Figure 5.1. 3D MCS include many features of
solid tumors that are missing in 2D monolayer cells and thus have been proven to better mimic
the native and complex tumor microenvironment [150].
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Figure 5.1. Illustration of the typical configuration of a 3D MCS over 500 µm in diameter [151]

The difference between using 3D MCS and 2D cell culture was demonstrated by many
researches [152, 153]. Colley et al. [154] reported that the delivery of drugs into the core of the
3D MCS model of head and neck squamous cell carcinoma cells is crucial for the therapeutic
effect while much lower exposure of the drug to the corresponding 2D monolayer cells
substantially decreased the cancer cell viability. In breast cancer treatment, Pickl et al. [152]
reported that the HER2 activation is enhanced in 3D MCS because the HER2 homodimer could
be formed in the model whereas only HER2/HER3 heterdimer, but not the HER2 homodimer
could be formed on the surface of monolayer cells. 3D MCS can be formed by many different
breast cancer cell lines, including TNBC[155-157]. Moreover, a pH gradient has been
demonstrated in 3D MCS model, a feature of the tumor microenvironment that would greatly
facilitate the characterization of the pH-sensitive fliposomes [158].
Therefore, 3D MCS can serve as a better platform for cancer research by providing a
more physiologically relevant microsystem. 3D MCS of TNBC can evaluate the efficacy of

89
fliposomes as a better prediction of fliposomes’ anticancer activities in vivo. The aim of this
chapter’s studies is to construct and characterize TNBC 3D MCS and evaluate the anticancer
efficacy on 3D MCS.
5.2 Materials and Methods
5.2.1 Materials. MDA-MB-231 and MDA-MB-468 cell lines were purchased from
ATCC (Manassas, VA, USA). Advanced F12/DMEM, Non-Essential Amino Acid (NEAA),
Collagen I, Bovine, Live/DEAD TM Cell Imaging Kit, Nigericin, Carboxy SNARF®-1,
acetoxymethyl ester, acetate, and Trypsin-EDTA were purchased from Thermo-Fisher. 96-well
Ultra-low Attachment Spheroid Microplates were purchased form Corning. HEPES and MES
were purchased from Fisher. Tris was purchased from Sigma-Aldrich.
5.2.2 Cell culture condition.
5.2.2.1 Cell culture maintenance. TNBC cell lines MDA-MB-231 and MDA-MB-468
were maintained in Advanced F12/DMEM supplemented with 5% fetal bovine serum (Gemini,
West Sacaramento, CA), 1% Penicillin-Streptomycin (Corning Life Science, Corning, NY) and
1% L-glutamine (Invitrogen, San Diego, CA). Cells were grown in 5% CO2 at 37 °C and
passaged at 85% confluence. (3~4 days).
5.2.2.2 3D MCS formation. MDA-MB-231 (~3000 cells/well), MDA-MB-468 (~2500
cells/well) were seeded in the Corning ultra-low attachment 96 well plates with 1% collagen.
The cells were centrifuged at 200 g for 15 minutes to facilitate the aggregation. The growth
media was changed every other day by replacing 100 μL of the media in the well with 100 μL
fresh media to maintain a 200 μL total media volume. The morphology of 3D MCS of each cell
line was observed on an inverted microscope.
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5.2.3 Live/dead cell assay. The LIVE/DEAD Viability/Cytotoxicity kit from
ThermoFisher was used to assess the viability of the cells inside 3D MCS according to
manufacturer protocol. Briefly, MDA-MB-468 cells (~2500 cells/well) were seeded in the
Corning ultra-low attachment 96 well plate to form 3D MCS using the methods described above.
At day 11-12 when the 3D MCS were at ~ 600 μm in diameter, three 3D MCS were transferred
to a glass bottom dish containing 100 µL of total growth media for each cell line. The
LIVE/DEAD cell imaging kit reagent was added to the 3D MCS at equal volume per well. The
3D MCS were incubated for 45 mins at room temperature, washed 3 times with PBS and imaged
using a Leica DMIRE2 confocal microscope. The live cells give a green fluorescence signal at
ex = 488 nm and em = 515 nm, while the dead cells give a nuclear read fluorescence signal at
ex = 570 nm and em = 602 nm. Images were acquired using the MetaMorph software and
analyzed using the ImageJ software.
5.2.4 pH gradient inside 3D MCS. The emission spectrum of Carboxy SNARF-1 shifts
along with the change of pH so Carboxy SNARF-1 can be used to measure the pH gradient
inside 3D MCS. Carboxy SNARF-1 is typically excited at one wave length between 488 nm and
530 nm and simultaneously emits fluorescent signal at two wavelengths, typically at about 580
nm and 640 nm. The pH can be determined by the ratio of these two fluorescent signals. MDAMB-468 cells (~2500 cells/well) were seeded in the Corning ultra-low attachment 96 well plate
to form 3D MCS using the methods described above. At day 11-12 when the 3D MCS were at ~
600 μm in diameter, three 3D MCS were transferred to a glass bottom dish containing 100 µL of
total growth media. SNARF-1 was dissolved in anhydrous DMSO at concentration of 100 μM
and added to 3D MCS in the glass bottom dish to a final concentration of 10 μM. The 3D MCS
were then incubated for 45 mins at 37°C, washed 3 times with PBS and imaged using a Leica
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DMIRE2 confocal microscopy. At the end of an experiment, 3D MCS loaded with Carboxy
SNARF-1 was exposed to three calibration solutions of 10 µM nigericin at pH 5.5, 6.8 and 8.0.
The solutions were composed of 140 mM KCl, 1 mM MgCl2, 0.5 mM EGTA and 20 mM MES
for pH 5.5, 20 mM Hepes for pH 6.8 or 20 mM Tris mM for pH 8.0. Three calibration images at
each pH were recorded in triplicate.

Figure 5.2. The emission Spectra of carboxy SNARF-1 indicates the correlation between pH and
the ratio of fluorescence at 580/640 nm [159]

𝑅−𝑅𝐵

pH = p𝐾𝑎 − log[𝑅

𝐴 −𝑅

×

𝐹𝐵(𝜆2)
𝐹𝐴(𝜆2)

]

The pH at a given point in the fluorescent images can be estimated using the above
equation, where the pKa of carboxy SNARF-1 is ~ 7.5, R is the ratio of the fluorescence
intensities at the two wavelengths λ1= 580 nm and λ2= 640 nm (Fλ1/Fλ2). Subscripts A and B

(1)
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represent the limiting values at the acidic and basic endpoints, respectively. From the equation
we can see pH is directly correlated to the R value - the higher R is, the lower pH would be.
However, the background signal needs to be subtracted before the calculation of R. Images were
acquired using MetaMorph software and analyzed using ImageJ software. One z-stack picture at
200 µm above the bottom of each 3D MCS was selected for the analyses and divided into five
areas using concentric circles. Each of the five areas was numbered 1 to 5 from the center to the
edge. The mean value of the two emission fluorescence signals of each region was measured.
The R value of each region was then calculated after subtracting the background noise. pH value
was then calculated by the above equation.
5.2.5 Cytotoxicity assays for DOX-loaded liposomes on 2D monolayer cells and on
3D MCS. MDA-MB-231 cells (~ 10,000 cells/well) and MDA-MB-468 cells (~ 5,000
cells/well) within 15 passages were seeded into 96-well plates and incubated at 37 °C with 5%
CO2 overnight. The complete medium was then replaced, respectively, with 200 µL culture
mediums containing DOX-loaded liposomes and free DOX at incremental concentrations. After
incubation for 72 hours, 20 µL CellTiter 96® AQueous One Solution cell proliferation assay
(Promega Corp., WI, USA) was added to each well when 100 µL complete growth medium was
replaced to stop treatment. After further incubation at 37 °C with 5% CO2 for 4 h, the
absorbance at 490 nm was recorded by Synergy HT microplate reader. The cells that were
exposed to only the growth media were assayed following the same procedure and taken as
100% viability reference. Samples were evaluated in quadruplicates.
MDA-MB-231 cells (~ 3,000 cells/well) and MDA-MB-468 cells (~ 2,500 cells/well)
within 15 passage were seeded into Corning ULA 96-well plate to form 3D MCS using the
method described above. After 11-13 days when the spheroids grew to ~600 µm in diameter, 3D

93
MCS were treated with free Dox and liposomal Dox at incremental concentrations in complete
medium. After incubation for 72 h at 37°C with 5% CO2, 3D MCS for each treatment group
were transferred to an opaque-walled 96-well plate with 100 µl medium in each well. An equal
volume of CellTiter-Glo 3D cell viability assay (Promega Corp., WI, USA) was added to each
well. The plate was shaken for 5 minutes and incubated for an additional 20 minutes at room
temperature to stabilize the luminescent signal. The luminescence was then recorded by a
Synergy HT microplate reader. The cells that were treated only with the growth media were
assayed following the same procedure and taken as 100% viability reference. Samples were
evaluated in quadruplicates.
5.2.6 Drug distribution in 3D MCS. The distributions of free DOX and DOX-loaded
liposomes within 3D MCS were determined by Laser confocal microscopy. MDA-MB-231 and
MDA-Mb-468 3D MCS with a diameter of about 600 µm were harvested 11~ 13 days after
seeding. All the 3D MCS were treated with 10 µg/ml free DOX or equivalent DOX-loaded
liposomes and incubated at 37 °C with 5% CO2 for 4 hours. The medium was then removed and
MCS were washed with PBS. The spheroids were transferred to a glass bottom dish and
observed on a Leica DMIRE2 laser confocal microscope with the following setup: Exposure
(1s), Gain (1x), Image Scaling (1000-7000) and z step (10 µm). The excitation and emission
were at 470 nm and 585 nm, respectively. Images were acquired using MetaMorph software and
analyzed using ImageJ software. The semi-quantitative analysis of mean fluorescence intensity
of free DOX, DOX-loaded liposomes in 3D MCS was made by calculating the mean
fluorescence intensity of each multicellular spheroids. All pixels’ fluorescence intensity of
regions of interest were counted and normalized by the area.
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5.2.7 Data analysis. Data are presented as mean ±standard deviation (SD) for the all
cytotoxicity assay study. IC50 was generated by nonlinear regression, log(inhibitor) vs. viability.
Response model using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA). The
statistical analysis was performed by one-way analysis of variance (ANOVA) for IC50
comparison using GraphPad Prism 6.0 Software. Tukey’s post hoc test analysis was performed
to compare between the treatment groups. The results with p < 0.05 were accepted as
statistically significant.
5.3 Results and Discussion
5.3.1 Formation of 3D MCS. Relatively tight multi-cellular spheroids of two TNBC cell
lines were successfully constructed at select seeding density after the application of
centrifugation and the use of collagen in the seeding media. As mentioned before, spheroids
with diameters larger than 500 µm commonly have a necrotic core surrounded by a viable layer
of quiescent zone and an outer shell of proliferating cells[160, 161]. The gradients of
metabolites, oxygen, nutrients and pH inside the 3D MCS make them a more physiologically
relevant platform for testing drug delivery systems than 2D cell models. The size of 3D MCS
gradually increased within 15 days and MDA-MB-231 formed tighter structure than MDA-MB468, shown in Figure 5.3. The growth curve of 3D MCS of MDA-MB-231 was validated with
the size and 3D viability assays (Figure 5.4).
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Figure 5.3. Morphology of MDA-MB-231 (3000 cells/well, upper) and MDA-MB-468 cells
(2000 cells/well, lower) after 5, 7, 9, 11, 13, 15 days in the ULA 96 well plates.

Figure 5.4. Growth Curve by size and 3D cell viability assay with MDA-MB-231 (3000
cells/well). Data presented as mean ±SD, N = 3.

5.3.2 Distribution of live and dead cells inside 3D MCS. Figure 5.5 shows the image
of a 100 m-deep cross section near the core of 3D MCS of MDA-MB-231 and MDA-MB-468
cells. The green signal from the fluorophore Calcein-AM represent the live cells while the red
signals from the fluorophore ethidium homodimer-1 represent the dead cells. The confocal
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images of both cell lines show that the green signals are concentrated in the peripheral areas,
indicating a proliferation zone while the red signals distribute mainly in the core, indicating a
necrotic zone. This phenomenon was also demonstrated by the semi- quantitative accumulation
of relative florescent signal at two wavelengths.
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Figure 5.5. Confocal Image of the distribution of live and dead Cells in MDA-MB-231 (upper
left) and MDA-MB-468 (lower left) 3D MCS. Live cells fluoresce green, dead cells fluoresce
red. The fluorescence intensity profiles (right) for both channels show the different distribution
of live and dead cells in the spheroid structure.

5.3.3 pH gradient in 3D MCS. Based on the equation (1) listed in section 5.2.4, the R
value is inversely proportional to the pH value. For an identified sample, RA, RB, FA(λ2) and
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FB(λ2) are constant, which means the pH is a function of a single variable R. The descending
trend was observed from the central area to the peripheral area of the concentric circles (Area 1
to Area 5). At the limiting acidic and basic conditions, RA, RB, FA(λ2) and FB(λ2) were selected
from the area closer to the edge of the same z-stack, which was equilibrated to the calibration pH
by the K+/H+ ionophore nigericin[162]. The intra-MCS pH decreased along the radius from the
edge to the core, which was listed in Table 5.1. Although the calculated pH value was greatly
impacted by the morphology and tightness of 3D MCS, the descending trend of pH inside 3D
MCS was validated. Therefore, 3D MCS is an excellent model to evaluate the efficacy of DOXloaded, pH-sensitive fliposomes in vitro.

Figure 5.6. Confocal Images of MDA-MB-468 3D MCS with SNARF-1 at two channels (green:
intensity at 580 nm channel, red: intensity at 640 nm channel)

Table 5.1. R value and calculated pH inside 3D MCS of MDA-MB-468
Area
1
2
3
4
R
0.47
0.45
0.32
0.25
pH
6.36
6.46
7.28
8.03

5
0.27
7.71
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5.3.4 Cytotoxicity assay for DOX-loaded liposomes on 2D monolayer cells and on 3D
MCS.
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Figure 5.7. Viability of MDA-MB-231 monolayer cells (left) and MDA-MB-231 3D MCS
(right) after 72 h drug exposure. Data presented as mean ±SD, N = 4.

Table 5.2. IC50 of Different Dox Formulations on 2D monolayer and 3D MCS of MDA-MB231 cells after 72 h exposure. Data presented as mean ±SD, N = 4.
DOXMORAZEIC50
Free
loaded Non
C16 DOXC16 DOX(µg/ml)
DOX
pH-sensitive
loaded
loaded
Liposome
Fliposome
Fliposome
0.646 ±
0.973 ±
0.781 ±
2D
0.091
0.387
0.207
6.88 ±
21.88 ±
13.07 ±
39.97 ±
3D
6.06
10.18
5.81
88.09

The fifty percent inhibitory concentration (IC50) value of each DOX or DOX-loaded
liposome formulation was calculated from data shown in Figure 5.7 using the GraphPad Prism
software. Against 2D monolayer of MDA-MB-231 cells, free DOX, DOX-loaded non pHsensitive liposome and fliposomes had similar IC50 values, where no statistically significant
difference was found among free DOX, non pH-senstivie liposome and MOR-C16 fliposome
groups. There was the same trend of IC50 values observed against 3D MCS of MDA-MB-231
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cells. IC50 value of each treatment group didn’t show statistical difference among all treatment
groups due to the large standard deviations. Based on IC50 value, ranking of anticancer efficacy
against 3D MCS was listed as free DOX > MOR-C16 fliposome > stealth liposome > AZE-C16
fliposome, as shown in Table 5.2.
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Figure 5.8. Viability of MDA-MB-468 monolayer cells (left) and MDA-MB-468 3D MCS
(right) after 72 h drug exposure. Data presented as mean ±SD, N = 4.

Table 5.3. IC50 of Different Dox Formulations on 2D monolayer and 3D MCS of MDA-MB468 cells after 72 h exposure. Data presented as mean ±SD, N = 4.
DOX-loaded
MOR-C16
AZE-C16
Non pHIC50 (µg/ml)
Free DOX
DOX-loaded
DOX-loaded
sensitive
Fliposome
Fliposome
Liposome
2D
0.045 ±0.012
0.095 ±0.031
0.083 ±0.017
0.153 ±0.056
0.285 ±0.202
0.375 ±0.215
0.333 ±0.303
3.01 ±3.44
3D

The anticancer activities against MDA-MB-468 cells gave a completely different profile.
IC50 value of free DOX was lower than any other treatment groups on 2D model. MOR-C16
Fliposome shared similar anticancer efficacy with conventional liposome, but only free DOX
and MOR-C16 Fliposome were significantly better than AZE-C16 Fliposome (p<0.05). To
compare IC50 values of different formulations of DOX against 3D MCS of MDA-MB-468 cells,
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there was no statistically significant difference among the groups of free DOX, conventional
liposome, MOR-C16 fliposome and AZE-C16 fliposome.
Comparing to evaluation anticancer efficacy by change of size and morphology [163165], evaluation by IC50 against 3D MCS is more convenient and accurate. Generally, IC50 value
of any treatment group against 3D MCS was much greater than the IC50 value against 2D
monolayer cells. This could be explained by the fact that penetration resistance was much higher
in the 3D MCS model, which reflected a much more realistic environment of tumor. However,
different TNBC cell lines exhibited different degree of the increase of the IC50. This
phenomenon could be explained by the different tightness of the MCS of different cell lines,
which affect the drug penetration and thus the drug activity. All of the results suggest that, after
long time exposure, the cytotoxicity was enhanced in 3D MCS but not in monolayer cancer cells.
This could be attributed to the enhanced release of DOX from the fliposomes, especially the
MOR-C16 fliposome, in the acidic environment inside 3D MCS.
5.3.5 Drug distribution inside 3D MCS. The selected formulation demonstrated
different levels of anticancer activity on the TNBC in vitro model between 2D monolayer cell
and 3D MCS. The difference is caused by many factors, of which one potential factor is the drug
penetration resistant in 3D MCS model. Full exposure of drug to 2D model enables the quick
equilibrium and complete cytotoxic effect, which is not seem in the 3D MCS as well as solid
tumor. The fluorescent signal of doxorubicin distributed inside 3D MCS gave us insight on how
the penetration resistance affected efficacy.
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Figure 5.9. Confocal Images of MDA-MB-231 3D MCS (cross section at 120 µm deep) Treated
with Free Dox (A), Dox-loaded Non pH-sensitive liposome (B) and Dox-loaded MOR-C16
Fliposome (C) for 4 h

After a 4 h incubation with different treatment groups of equivalent amount of DOX,
confocal microscopy images of cross sections of MDA-MB-231 3D MCS at about 120 µm from
the bottom were taken and the fluorescent signal of DOX was analyzed (Figure 5.9). Stronger
fluorescent signals of MCS that were treated with liposomal DOX were observed in comparison
to those treated with Free DOX. An intense ring of DOX accumulated was observed in the outer
proliferative cells of each 3D MCS, indicating limited penetration of all formulations into MCS
after 4 h incubation.
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Figure 5.10. Confocal Images of MDA-MB-468 3D MCS (cross section at 120 µm deepth)
treated with Free DOX (A), DOX-loaded conventional liposome (B), DOX-loaded MOR-C16
Fliposome (C) and DOX-loaded AZE-C16 Fliposome (D) for 4 h

No qualitive difference of fluorescent intensity was observed among groups of MDAMB-468 3D MCS after treatment by free or liposomal DOX for 4 h except for AZE-C16
Fliposome (Figure 5.10). This result suggests that both free DOX and DOX-loaded liposomes
could penetrate into MDA-MB-468 3D MCS with similar efficiency given 4 h of exposure time.
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When the penetration of DOX into 3D MCS of two TNBC cell lines was compared with
the penetration of liposomal DOX (4 hour of exposure time), the liposomal DOX groups showed
more penetration than the free DOX in 3D MCS of MDA-MB-231 cell lines, but no qualitive
difference of penetration into 3D MCS of MDA-MB-468 was observed between liposomal DOX
and free DOX. This phenomenon indicated the association between the cell line that formed the
3D MCS and the DOX penetration into the 3D MCS, which was consistent with the report by
Namhuk, et al. [163]. Cellular accumulation and uptake of a weakly-basic drug, such as
doxorubicin has been reported to decrease along with lower extracellular pH [166-168]. At low
pH in the MCS interstitium, such as area 2 in Figure 5.6, the ionized DOX has low lipid
solubility and high electrical resistance, thus a greatly reduced membrane penetration. If one cell
line could form tight spheroid, such as MDA-MB-231, the diffusion of free DOX would be
limited by such resistance. However, if the cell line could only form loose aggregate, such as
MDA-MB-468, the penetration wouldn’t be the limiting step for the cytotoxic effect of the
anticancer agent. Therefore, the enhanced cytotoxicity of the DOX-loaded fliposomes in
comparison to conventional liposome, both of which has similar size and surface charge, could
be attributed to the enhanced release of the fliposomes in response to the reduced pH inside the
3D MCS, rather than differences in liposomal drug distribution.
The confocal scanning of 3D MCS was performed with z-stack sectioning of 10 µm per
step from the bottom to top. The 100 µm depth was chosen due to the limit of the confocal laser
scanning technique [169]. The degree of light penetration is greatly affected and reduced by the
scattering in the sample and the defocusing of the illumination beam when the light travels over
100 µm through sample [170, 171]. Therefore, the fluorescent signal at 100 µm depth from
bottom was acceptable for comparison across different MCS without impact of light penetration
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issues. Multiphoton microscopy can be utilized in the future studies since the excitation photon
would be split into multi photons which carry the same energy as a sum but have much longer
wavelength for deeper penetratioin [172]. Still this technique can only enhance the penetration
of the excitation photons, but not the emission photons. Cryosection is another alternative way
to address the light penetration issue by cutting the spheroids into sections of 10 – 20 µm in
thickness. High resolution images of each section can then be easily obtained using confocal
microscopy [173]. The drug distribution in the cryosections could also be directly measured by
MALDI Imaging Mass Spectrometry [174].
5.4 Summary
3D MCS of TNBC was successfully established for in vitro efficacy evaluation. Cell
viability and pH gradient inside 3D MCS were validated to confirm that MCS possess the
essential microenvironment as an appropriate model to evaluate pH-sensitive liposomes. Free
DOX, DOX-loaded conventional liposome and DOX-loaded Fliposome were evaluated in 3D
MCS model. DOX-loaded Fliposome, especially the MOR-C16 fliposome (DPPC : Mor-C16 :
PEG-Ceramide = 70 : 25 : 5), showed improved efficacy than the conventional liposome (DPPC
: Chol : PEG-Ceramide = 70 : 25 : 5) based on IC50 value.
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Chapter 6: Evaluation of Anticancer Efficacy of Doxorubicin-loaded Fliposome in Mice

6.1 Introduction
Animal models are still the most important evaluation tools to bridge the gap between the
discovery of drug candidates in vitro and their clinical development. Although many innovative
techniques and mechanistic studies have emerged to allow better prediction of a drug candidate’s
efficacy and safety from its data in vitro, animal models, especially mice models in oncology are
still essential in evaluating a drug candidate before any further trial in human [175]. The animal
models in oncology are typically utilized to simulate a cancer’s invasion, metastasis and
therapeutic response to the new drug candidate. Therefore, robust and relevant animal models
are paramount to test our hypothesis after tremendous work in formulation and in vitro
evaluation.
Human tumor xenograft models in nude mice stand out from various animal models
because of the low cost, ease to handle and numerous support information [176]. Since the first
mouse leukemia models grown as ascites back to 1960, tremendous effort has been devoted to
build various tumor models in mice by millions of scientists [177]. For breast cancer, the
xenograft models was successfully established in 1969 [178] and the orthotopic metastatic breast
cancer was established by transplanting a patient-derived xenograft fragment into the nude
mouse fat pad in 1993 [179]. Generally, there are different types of in vivo mouse model of
breast cancer, including cell-derived xenografts (CDX), patient-derived xenografts (PDX) and
genetically engineered mouse models (GEMM) [175]. It is widely accepted that the xenograft
models are inferior to the GEMM due to immunodeficiency, but CDX is widely accepted for
evaluating the response of human tumor to the therapy because PDX is severely limited by the
resource [180]. Among the CDX of breast cancer, the ectopic CDX model which implants
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human tumor cells subcutaneously into the immunocompromised mouse is most commonly used
because it is fast, cheap and technically simple but still involves human breast cancer cells.
However, this subcutaneous model does not appropriately reflect the reality of breast cancer. In
particular, the perfusion of blood in such subcutaneous tumor is more than the tumor in situ,
which exaggerates the EPR effect. In contrast, an orthotopic CDX model of breast cancer
implants human breast cancer cells in the murine mammary gland/fat pad, which would provide
the xenograft a microenvironment similar to that of breast cancer while the xenograft tumor size
is still measurable with calipers. In addition, sex hormone levels play a critical role in the
tumorigenesis of TNBC, which makes the orthtopic TNBC xenograft mice model an excellent
system to evaluate the efficacy of fliposome. Nevertheless, it must be noted that the
immunodeficient mouse model of orthotopic implantation doesn’t perfectly reproduce the
tumorigenesis in human because the host immune cells at the tumor site would also play
important roles in the genesis, progression and metastasis of a TNBC tumor [181].
Generally regression of tumor and longer survival is utilized in clinical studies to indicate
the efficacy of the therapy. Some studies failed to achieve observable tumor regression because
the administration of sub therapeutic doses, in which less cytotoxicity can prolong the duration
of study. Overall tumor volumes were calculated and compared to non-treatment or reference
treatment to assess efficacy. The timing of dosing the drug candidate is a key parameter that
affects the outcome of such an experiment. A “tumor growth delay study” is more reliable for
assessing the potential of a treatment because the first dose is initiated after the appearance of the
solid tumor rather than before the appearance of a small solid tumor, which is known as “tumor
growth inhibition study”.
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Preparation of doxorubicin in a liposomal formulation can change the pharmacokinetics
and pharmacodynamics of the drug to achieve lower toxicity and higher efficacy of the therapy
[38]. Hence, information on the pharmacokinetics of fliposome will help us better understand
the correlation between its in vitro feature and in vivo efficacy and safety. The aim of this
Chapter’s studies is to determine the efficacy of the DOX-loaded pH-sensitive fliposome as
compared to conventional liposomes against TNBC on the orthotopic xenograft mouse model.
6.2 Materials and Methods
6.2.1 Materials.
6.2.1.1 Chemical agents. Isoflurone, ketamine, xylazine, and heparin were purchased
from Patterson Veterinary (Saint Paul, MN). High-performance liquid chromatography (HPLC)grade acetonitrile, and acetic acid were purchased from Fisher Scientific (Fair Lawn, NJ).
6.2.1.2 Animals. For the pilot pharmacokinetic study, jugular vein-cannulated female
athymic nude mice (NU- Foxn 1nu) were obtained from Charles River at 8 weeks of age; for
anticancer efficacy evaluation, female athymic nude mice (NU- Foxn 1nu) were obtained from
Charles River at 5 weeks of age. The in vivo study was performed based on the animal protocol
(No. 16R0r) which was approved by the Institutional Animal Care and Use Committee
(IACUC), University of the Pacific. The mice were housed in a temperature-controlled room
with a 12-hour day/night lighting cycle and were housed individually if cannulated. All mice
were fed standard murine chow and water ad libitum.
6.2.2 Pilot pharmacokinetic study.
6.2.2.1 Pilot pharmacokinetic study design. The DOX-loaded AZE-C16 fliposome
listed in the 4.3.5 (5 mg/kg equivalent doxorubicin) was administered via jugular vein cannula to
female mice. Blood samples (100 µL) were gently withdrawn from the jugular vein cannula
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followed by fluid replacement (equivalent volume) with sterile saline at each time point. The
assignment of mice sampled, and the time point was shown in Table 6.1. The total blood volume
withdrawn (excluding terminal samples) was no greater than 10% of the animal’s total blood
volume within first 24 hours. At terminal time point (48 or 72 hour), animals were anesthetized
(isoflurane: 2-3% induction and 1-2% maintenance) and blood sample was taken by cardiac
puncture. All blood samples were mixed with sterilized water at volume ratio 1:2 in order to lyse
all blood cells. The samples were then stored at -20℃ until further analysis.

Table 6.1. Sequential assignment of sampling in pilot pharmacokinetic study (six mice coded by
letter A through F)
Time(hr)
1
2
8
24
48
72
Mice to be sampled A
A
D
E
A
B
D
B
B
F
C
D
E
F
C
C
E
F

6.2.2.2 Sample preparation. DOX (1000 µg/mL) and Daunorubicin (1000 µg/mL) were
prepared in methanol and stored at -20 °C. The solutions of DOX were further diluted with
methanol to give a series of standard solutions at 0, 1, 2, 20, 100, 200, 1000 μg/ml DOX
concentrations. Then 2.5 μl standard solutions were added into 47.5 μl lyzed blood to obtain the
standard whole blood working solutions with at 0, 0.1, 1, 5, 10, 50 μg/ml DOX concentrations.
Whole blood working solutions for quality control (QC) were prepared separately at 0.1, 5 and
50 μg/ml DOX for low QC, moderate QC and high QC, respectively. For standards and quality
controls, 2.5 μl of Daunorubicin (100 μg/ml) was added into 150 μl of water-lysed standard
whole blood working solution or QC solution. For each unknown lysed whole blood sample, 2.5
μl of Daunorubicin (100 μg/ml) was added to 150 μl lysed blood water mixture sample. 850 μl
of acetonitrile with 1% formic acid was added to all samples and standards to precipitate plasma
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proteins. The DOX was de-chelated from Copper by sonication at 55°C for 25 minutes followed
by centrifugation at 10000 rpm for 20 minutes at 4°C. 10 μl of the supernatant was aliquoted for
analysis.
6.2.2.3 LC/MS/MS assay. The LC/MS/MS system included an Agilent 1100 series
HPLC consisting of an online degasser, a binary pump, and an auto-sampler (Agilent
Technologies, Santa Clara, CA) and an MDS Sciex API 3000 triple – quadruple tandem mass
spectrometer equipped with a turbo ion spray (Applied Biosystems, Foster City, CA). 10 μl of
sample was injected into a PLRP-S C18 column (150 × 2.1 mm i.d., 3-μm particle size; Varian
Palo Alto, CA) with a ZORBAX RELIANCE C18 Guard column (12.5 × 4.6 mm i.d., 5-μm
particle size; Agilent, Santa Clara, CA). Mobile phase A was 0.1% formic acid in doubledistilled water. Mobile phase B was 0.1% formic in acetonitrile. A gradient elution with a flow
rate of 250 μl/min was used to separate the compounds (Table 6.2). The total running time is 15
minutes. The mass spectrometer was operated in positive ionization mode with multiple reaction
monitoring. Table 6.3 shows the detail of the mass spectrometer parameters of Doxorubicin and
Daunorubicin.

Table 6.2. Gradient elution program
Time (min)
0
4
A%
80
50
B%
20
50

4.03
5
95

5.3
5
95

6
80
80

15
20
20
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Table 6.3. Mass spectrometer parameters for MRM of Doxorubicin
Parameter (units)
Doxorubicin
Q1/Q3
544.2/397.2
Declustering potentials (volts
11
Focusing Potential (volts)
70
Collision Enegery (volts)
15
Collision Cell exit potentials (volts)
22

Daunorubicin
528.3/363.2
16
120
33
30

6.2.2.4 Data analysis. Data are presented as mean ±standard deviation (SD) for the
pharmacokinetic study. Non-compartmental analysis of the whole blood concentration time
profiles was conducted in Phoenix WinNonLin to obtain AUCinf, Lambda_z and total clearance
(CL). Subsequently, the elimination half-life was calculated with the formula: t1/2 =
ln2/Lambda_z.
6.2.3 Anticancer efficacy evaluation on a TNBC orthotopic model.
6.2.3.1 Establishment of TNBC orthotopic xenograft model. The MDA-MB-468 cells
were cultured and maintained in the Advance DMEM/F12 medium as described previously. On
the day of the experiment, the cells were trypsinized and re-suspended in medium followed by
centrifugation at 200 g for 5 minutes. After aspiration of the supernatant, the cell pellet was
washed twice with PBS. A cell counting by a Scepter™ 2.0 Handheld Automated Cell Counter
(MilliporeSigma, Burlington, MA) was performed with the re-suspended cells in sterile PBS.
Lastly the cells were re-suspended in the cold HBSS/Matrigel® Matrix (vol : vol = 1:1) mixture
containing 0.04% Dnase, of which the cell density is approximately 8×108 cells/ml. The cells
suspension was maintained on ice until injection.
For the ease of performing the orthotopic injection of tumor cells, the mice were
anaesthesized (isoflurane: 2-3% induction and 1-2% maintenance). The MDA-MB-468 cells
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(8,000,000 cells/ mouse) were injected into the mammalian fat pad using a 27 gauge needle on
the second nipple around the left axillary region of mice. Following inoculation, the mice were
observed daily for their general health and appearance of tumors.
6.2.3.2 Study design. The tumors were allowed to grow up to 70 - 100 mm3 for 2 weeks
after inoculation. The tumor bearing mice were randomly divided into five groups (control,
doxorubicin solution, conventional liposome, MOR-C16 fliposome and AZE-C16 fliposome)
with eight mice per group except for the control group (N=5). Stratified randomization was
based on size of tumor. Afterwards, 5 mg/kg free doxorubicin, conventional liposome (5 mg/kg
equivalent doxorubicin) and fliposomes (5 mg/kg equivalent doxorubicin) were diluted in
sterilized PBS and administered to the mice once a week for 4 weeks, while PBS (100 μL) was
administered as a control to evaluate the effect of no treatment. The animals were anesthetized
with isoflurane and the formulations were injected through tail vein. Body weight was recorded
and monitored to evaluate the safety; tumor size (in mm3) was measured with calipers every
other day, and the tumor volume was calculated using the formula:
𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑚3 ) =

1
× 𝐿 × 𝑆2
2

where L the long axis and S is the short axis of the tumor lump. The tumor and hearts
were removed and weighted when the animals were euthanized by anesthetics overdose after 63
days post first dosing.
6.2.3.3 Data analysis. Data are presented as mean ±standard error of mean (SEM) for
the anticancer efficacy study due to large deviation of tumor volume based on measurement.
The statistical analysis was performed by two-way analysis of variance (ANOVA) for the
antitumor efficacy study using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA).
Tukey’s post hoc test analysis was performed to compare between the treatment groups. The
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correlation analysis was performed for comparing the tumor volume measurement and the tumor
weight. The results with p < 0.05 were accepted as statistically significant.
6.3 Results and Discussion
6.3.1 Doxorubicin LC-MS/MS assay. The retention time for Doxorubicin and
Daunorubicin was 6.65 and 7.18 minutes respectively. The standard curve in blood is from 0.1
to 50 μg/ml Doxorubicin (Figure 6.1) based on weighted regression (1/y) analysis (r2 >0.99) of
the peak area ratio (Doxorubicin/Daunorubicin) versus Doxorubicin concentration. LOD and
LOQ is 0.01 and 0.1 µg/ml, respectively.

Figure 6.1. Standard curve (0.1 to 50 µg/ml) of AZE-C16 fliposome Doxorubicin in blood (n=3,
r2= 0.9970)

6.3.2 Pilot pharmacokinetic analysis. Figure 6.2 shows the average Doxorubicin
concentration in blood of 6 mice (n =3/ timepoint) versus time after 5 mg/kg IV administration.
Due to the low sensitivity of analysis assay, the concentration of the last three time points fell
below the LOQ but above LOD, therefore the point of 24 hour was presented as the LOQ and 48
and 72 hours were not used for analysis. The concentration of DOX in blood dropped quickly to

113
lower than 0.3 µg/ml (the IC50 value on 3D MCS) within 12 hours. The pharmacokinetic curve
showed the feature of two-compartmental model, which was not consistent with the reported
three-compartmental model in the literature [182]. The values of area under the plasma
concentration-time curve (AUC) and total clearance were in between of the values of pegylated
liposome and free doxorubicin reported in the literature [183]. Elimination half-life calculated
from the 8- and 24-h values was approximately 6.5 h, which was close to the value of free dox
[184]. Comparing to the data listed in the literature [182-184], the pharmacokinetic profile of
AZE-C16 fliposome was more similar with free doxorubicin other than pegylated liposomal
doxorubicin, suggesting doxorubicin may leak prematurely from AZE-C16 fliposome during
circulation before accumulation at the tumor site.

Figure 6.2. Doxorubicin blood concentrations following intravenous administration of DOXloaded AZE-C16 fliposome (5 mg/kg equivalent doxorubicin) to female nude mice. Data
presented as mean ±SD, N = 3.
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6.3.3 Anticancer efficacy of pH-sensitive liposomes on TNBC orthotopic model. The
anticancer activity of fliposome was investigated using the above-mentioned orthotopic MDAMB-468 xenografts nude mouse model. The treatment was started at a mean tumor size of 75
mm3, and no tumor regression was observed. Figure 6.3 shows the effect of different
formulations on tumor volumes measured every other day for nine weeks. The statistical
analysis was performed using two-way ANOVA with data up to 61 days post first dose, after
which the deviation within each group was getting larger. Turkey post test comparisons between
treatment groups showed that tumor volume of MOR-C16 treatment group was significantly (p <
0.05) smaller than the one of free DOX treatment group from day 57 to 61, and significantly (p <
0.05) smaller than the one of conventional liposome group at day 61. There was a clear trend
that the tumor progression of fliposome (MOR-C16 and AZE-C16) treatment groups was
delayed compared to free DOX and conventional treatment group, which suggested the pHsensitive liposome did improve the anticancer activity against TNBC in an orthotopic xenograft
model. In addition, the tumor weight was correlated with the tumor volume at the end of the
experiment, confirming that the tumor volume measurement accurately reflected the tumor
progression with R = 0.7833 and p < 0.001 (Figure 6.4).
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Figure 6.3. Anticancer efficacy of DOX formulations in mouse orthotopic xenografts bearing
MDA-MB-468 breast cancer. MDA-MB-468 cells were inoculated into the mammalian fat pad
in the axillary of femal athymic nude mice. The animals received ~100 µL of normal saline as
control or 5 mg/kg of DOX in PBS or 5 mg/kg of equivalent DOX-loaded liposome on 0, 7, 14,
21 days (indicated by arrows). The data represent mean ±SEM of results calculated from 5 or 8
animals. * Significant difference (p<0.05 for two-way ANOVA) observed between MOR-C16
and Free DOX group, # Significant difference (p<0.05 for two-way ANOVA) observed between
MOR-C16 and conventional liposome group.
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Figure 6.4. Correlation analysis of tumor weight and tumor volume at the end of experiment on
Day 63 after the first IV injection (n = 37 total).

Although there was statistically significant difference shown in limited days between the
fliposome groups and the other groups, a benefit of pH-triggered release as a passive targeting
strategy was still observed. There are several areas that could be improved for future
investigations. First, the orthotopic breast cancer model could be improved by injecting TNBC
cell at exponential phase under more robust conditions, which will facilitate tumor progression
so that the tumor volume will have more apparent difference between different groups, which
would provide better chance to observe statistically significant differences. 3D MCS of breast
cancer cells could also be inoculated into the mammalian fat pad instead of the suspended cancer
cells to form a more uniform size of tumor, which will reduce the deviation within each group.
Secondary, another TNBC cell line could be chosen for further animal studies. According to our
cell culture studies, the liposomal doxorubicin will be more advantageous in the anticancer
activities when the cell line could form tighter spheroids rather than loose aggregates in culture.
The fold of increase of the IC50 value from 2D monolayer to 3D MCS would be a good indicator
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to construct animal models that bears tighter solid tumors. Thirdly, the therapeutic benefits of
pH-triggered release against solid tumors rely first on the intratumoral accumulation of the
formulation by the EPR effect. Therefore, sufficient duration of circulation in blood, which is a
key indicator of liposome stability in vivo is a major concern for the design of triggerable
liposomes. It was reported that 24 hour circulation is required for the manifestation of the EPR
effect[138], and the total amount of DOX eventually displaying a therapeutic effect at tumor site
would determine the utmost contribution by triggered release. According to the pilot
pharmacokinetic study, the AZE-C16 fliposome, which has better and quicker response upon
lower pH , was less stable in the blood circulation than the reported conventional liposomes
[184]. The less efficacy obtained of AZE-C16 fliosome compared to MOR-C16 could be
explained by unexpected premature leakage during the blood circulation, leading to the quick
dropping of drug concentration in blood within 8 hours and the insufficient intratumoral
accumulation through the EPR effect. As an improvement, the optimization of formulation
should highlight stability as a priority, especially stability at 24 hours to provide a fundament for
sufficient circulation of the delivery system under study.
6.3.4 Cardiotoxicity evaluation. During the whole experiment, no mice showed drastic
decrease of the body weight. It is also reported that heart weight to body weight ratio would
decrease when doxorubicin accumulated excessively into the heart [185, 186]. In this study, the
heart weight to body weight ratio among all treatment groups had no significant difference
compared to the non-treatment group (Figure 6.5). All the animals possessed steady body
weight. It was reported that the median cumulative cardiotoxic dose of doxorubicin was 36.4
mg/kg found in the mouse [187], which was much higher than our experiment design. In order
to get better tumor regression efficacy, higher dosage of liposomal doxorubicin could be used in
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future research. Lastly, the administration of free DOX induces the accumulation of reactive
oxygen species in heart. Therefore, cardiotoxicity would be another safety issue that warrants
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further investigation in the future.
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Figure 6.5. Effect of doxorubicin and liposomal DOX on the heart weight to body weight ratio
as an indicator of doxorubicin-induced cardiotoxicity in nude mice on Day 63 after the first IV
injection. The data represent mean ±SD of results calculated from 8 animals (Saline group
N=5). One-way ANOVA followed by Tukey's multiple comparison test suggested no significant
differences between different treatment groups.
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6.4 Summary
An orthotopic TNBC xenograft mice model was successfully established for in vivo
efficacy evaluation. Anticancer activity of free DOX, DOX-loaded conventional liposome and
DOX-loaded Fliposome was evaluated in the orthotopic xenograft model by monitoring the
tumor progression for 61 days. DOX-loaded Fliposome, especially the MOR-C16 fliposome
(DPPC : Mor-C16 : PEG-Ceramide = 70 : 25 : 5), showed improved efficacy than the
conventional liposome (DPPC : Chol : PEG-Ceramide = 55 : 40 : 5) which was suggested by the
delay of the tumor progression. The AZE-C16 fliposome was less effective than the MOR-C16
fliposome probably due to its lower stability, which was observed in its in vitro release profile
and in the pilot pharmacokinetic study. The quick response of AZE flipids to lower pH, also
suggested by the estimated pKa value of 6.8, compromised the stability of liposome. Further
investigation is needed to balance the pH-sensitivity and stability in vivo.
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Chapter 7: Summary and Future Work

Breast cancer is a major health care concern and the second leading cause of death
affecting American women. Triple negative breast cancer is characterized by lack of expression
of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth
factor receptor (HER2 /neu). It is the leading fatal subtype of breast cancer with the poorest
prognosis. Chemotherapy, individually or in combination with surgery or radiotherapy is
predominantly given to TNBC patients since TNBC is not responsive to targeted therapies.
Doxorubicin is one of the most effective drugs used in the treatment of TNBC, but it has serious
adverse effects, especially cardiotoxicity associated with the accumulation use of free drug.
Liposomes are one of the widely used drug delivery systems to facilitate physical targeting, in
which preferred accumulation is achieved by the EPR effect for the treatment of solid tumors.
Stimuli-response, such as a reverse pH gradient at tumor site, can ramp up the release rate of
anticancer agent, consequently makes more free drug available to exert its biological effect. A
combination of a physical targeting approach with a pH triggered release strategy can have a
significant impact on overall effectiveness of the therapy against TNBC. The objective of this
dissertation work was to develop and evaluate doxorubicin loaded pH-sensitive liposomes for
drug delivery against TNBC.
pH-sensitive fliposomes with conformational switch lipids were successfully prepared by
thin film hydration. In order to have a standardized procedure, ethanol injection followed by
tangential flow filtration was developed to prepare fliposomes. The metal ion remote loading
method was developed to circumvent the increasing proton concentration caused by the
traditional ammonium gradient remote loading methods. Fliposomes carried high encapsulation
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efficiency (>80%), small mean particle size (<200 nm) and small PDI (<0.3), indicating the
robustness of the preparation procedure.
It is critical to have a reliable method to evaluate pH-sensitivity of fliposomes in vitro
since the release of our delivery system is triggered by the reverse pH gradient at the tumor site.
Several release assays for DOX-loaded liposomes, including traditional dialysis methods,
fluorescent methods and our new resin adsorption methods were evaluated. Adsorption of
positive charged doxorubicin onto the cellulose membrane of dialysis tubing made dialysis not
reflect the real release profile while various degradation rates of DOX in different pH buffer
reversed the intensity of fluorescent measurement. Taking the complexity of the operation
procedure into consideration for high throughput evaluation, the direct resin adsorption method
appears to be the most practical and feasible method to kinetically monitor the release profile of
pH-sensitive liposomes in vitro. The pH-sensitivity of fliposomes evaluated by direct resin
adsorption method was validated with calcein loaded fliposomes, in which calcein is a
commonly used water-soluble fluorescent probe for investigating drug release from liposomes.
The pH-sensitive release of doxorubicin from fliposomes was similar with the release of calcein
in fliposomes.
In order to maximize the benefit of liposomes for anticancer therapy, the properties of
fliposomes need to be optimized to achieve effective physical targeting and pH-sensitive release.
In addition to triggered release, which is a focus for this dissertation, stability, small and
homogeneous size, and adequate drug-loading capacity are all important properties of liposomes
for anticancer therapy. All those physical properties except for size are related to components of
liposomes other than the preparation procedure. Therefore, identification of the factors
impacting the outcome of physical targeting and the optimization of fliposomes were based on
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the lipid composition in this dissertation. The neutral pegylated lipid, PEG-Ceramide was
chosen for enhanced pH-sensitivity. Cholesterol and long hydrocarbon tail phospholipid, such as
DSPC were necessary for the stability of the liposomes, while the incorporation of cholesterol
and DSPC compromised the release in response to the desired pH. With an increasing mole
percentage of flipid, the pH-sensitivity of fliposomes was increased, while the homogeneity, and
consequently in vivo stability was sacrificed, indicated by a drastic increase of size and PDI. In
early studies, AZE-C16-based fliposomes showed quick response of release to the desired pH,
but less stability. RSM was utilized to further optimize the AZE-C16 based fliposome. AZE:
DSPC: Chol: PEG-Ceramide = 38: 32: 25: 5 was predicted by RSM to have relatively high
stability and pH-sensitivity.
Before evaluating the efficacy in an in vivo model, we evaluated the anticancer efficacy
of fliposome in vitro. 3D MCS are self-assembled cultures of tumor cells formed in conditions
where cell-cell interactions predominate over cell-substrate interactions. 3D MCS include many
features of solid tumors that are missing in 2D monolayer cells, especially the reverse pH
gradient. Therefore, 3D MCS mimic the native and complex tumor microenvironment, thus can
serve as a valid and clinically relevant in vitro model to evaluate efficacy of fliposomes. Two
3D TNBC MCS, MDA-MB-231 and MDA-MB-468, were successfully established for in vitro
efficacy evaluation. Cell viability and the pH gradient inside 3D MCS were validated by laser
confocal microscopy to confirm that MCS possess the essential microenvironment. Free DOX,
DOX-loaded conventional liposomes and DOX-loaded fliposomes were evaluated in the 3D
MCS model for anticancer efficacy. IC50 value for all treatment groups against 3D MCS was
much greater than the IC50 value against 2D monolayer cells, which could be explained by the
fact that penetration resistance was much higher in the 3D MCS model. DOX-loaded
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Fliposomes, especially the MOR-C16 fliposome (DPPC : Mor-C16 : PEG-Ceramide = 70 : 25 :
5), showed improved efficacy than the conventional liposome based on IC50 value.
A pilot pharmacokinetic study of AZE-C16 fliposome was conducted in female athymic
nude mice due to concerns of stability with AZE-C16 fliposomes. The results showed that the
concentration of DOX in blood dropped quickly lower than 0.3 µg/ml (the IC50 value on 3D
MCS) within 12 hours. The pharmacokinetic profile of AZE-C16 fliposomes was similar with
free doxorubicin, which indicated premature leakage from AZE-C16 fliposomes in circulation.
A pharmacokinetic study of MOR-C16 fliposomes is also needed to correlate with the in vitro
stability and pharmacokinetic study with the eventual efficacy results and compare the outcome
of AZE-C16 and MOR-C16 fliposome. Increasing the dose or improvement in the analytical
assay could possibly solve the problem of LOQ, which will give better insight into fliposome in
vivo. The antitumor efficacy of pH-sensitive fliposomes was evaluated in an orthotopic MDAMB-468 xenograft in a nude mouse model, which was the first time that the DOX-loaded
liposomal formulation conducted the treatment on TNBC orthotopic model. DOX-loaded
Fliposomes, especially the MOR-C16 fliposomes showed improved efficacy compared to
conventional liposomes at day 61 post-first dose, which was suggested by the delay in tumor
progression.
As potential work for comprehensive development of fliposome, the further optimization
of fliposome by RSM, including MOR-C16 flipsome, is very critical. The stability within 24
hours should be ranked as the highest priority compared to pH-sensitivity based on current
research. In addition, the percentage of components should cover wider range for better
prediction. If needed, the independent variables could be added to three factors (flipid%,
phospholipid% and cholesterol%), by which more interaction could be investigated. On the
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other hand, the biodistribution and comprehensive pharmacokinetic studies are necessary to
investigate doxorubicin exposure to the TNBC as well as normal tissue. Doxorubicin exposure
through the EPR effect can be obtained by comparing the drug concentration in tumor of
fliposome and one of pegylated liposome, therefore the contribution from pH-triggered release
can be estimated if there is difference suggested in the efficacy with two treatments. Regarding
the efficacy evaluation, dose escalation to achieve better tumor regression is another potential
study for comprehensive experiment design once the final optimization is done.
There is another perspective need further investigation, which is the correlation between
in vitro characteristics and in vivo outcome. The characterization of fliposomes in vitro, such as
stability or pH sensitivity, is the most common and convenient method to investigate the
property of fliposomes. We also have developed the 3D MCS platform to evaluate the
anticancer efficacy of fliposomes. How to link different tools in vitro with the outcome of in
vivo model is critical, for instance, the identification of which characteristic in vitro has the most
impact on the exposure in 3D MCS, consequently influencing half-life in vivo. Once the
correlation is established, different strategies aiming at various in vivo profile can be achieved by
manipulation of parameters of fliposomes, such as size and particular components.
In conclusion, pH-sensitive fliposomes were successfully prepared by thin film hydration
and ethanol injection methods with appropriate properties for physical targeting. Direct Resin
adsorption method was established to evaluate pH-sensitivity of fliposome in vitro. 3D MCS
and orthotopic TNBC models were successfully established for efficacy evaluation.
Doxorubicin-loaded fliposomes, especially the MOR-C16 fliposome showed improved
anticancer efficacy over non pH-sensitive liposome in vitro and in an orthotopic TNBC
xenografts mouse model.
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